PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
15078549-8	2004	The trophic effects of CRF and urocortin are mediated by the protein kinase A and mitogen-activating protein kinase pathways.	Urocortins	31-40	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	61-77
34351805-4	2021	Urocortin-induced increase in cardiac tolerance to I/R depends mainly on the activation of corticotropin-releasing hormone receptor-2 (CRHR2) and its downstream pathways including tyrosine kinase Src, protein kinase A and C (PKA, PKCepsilon) and extracellular signal-regulated kinase (ERK1/2).	Urocortins	0-9	corticotropin releasing hormone receptor 2	Homo sapiens	91-133
34378854-8	2021	We applied meta-regression to explore the association between left ventricular ejection fraction and serum urocortin 1 and urocortin 2 levels.	Urocortins	107-118	urocortin 2	Homo sapiens	123-134
34351805-4	2021	Urocortin-induced increase in cardiac tolerance to I/R depends mainly on the activation of corticotropin-releasing hormone receptor-2 (CRHR2) and its downstream pathways including tyrosine kinase Src, protein kinase A and C (PKA, PKCepsilon) and extracellular signal-regulated kinase (ERK1/2).	Urocortins	0-9	corticotropin releasing hormone receptor 2	Homo sapiens	135-140
34351805-4	2021	Urocortin-induced increase in cardiac tolerance to I/R depends mainly on the activation of corticotropin-releasing hormone receptor-2 (CRHR2) and its downstream pathways including tyrosine kinase Src, protein kinase A and C (PKA, PKCepsilon) and extracellular signal-regulated kinase (ERK1/2).	Urocortins	0-9	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	196-199
34351805-4	2021	Urocortin-induced increase in cardiac tolerance to I/R depends mainly on the activation of corticotropin-releasing hormone receptor-2 (CRHR2) and its downstream pathways including tyrosine kinase Src, protein kinase A and C (PKA, PKCepsilon) and extracellular signal-regulated kinase (ERK1/2).	Urocortins	0-9	protein kinase C epsilon	Homo sapiens	230-240
34351805-4	2021	Urocortin-induced increase in cardiac tolerance to I/R depends mainly on the activation of corticotropin-releasing hormone receptor-2 (CRHR2) and its downstream pathways including tyrosine kinase Src, protein kinase A and C (PKA, PKCepsilon) and extracellular signal-regulated kinase (ERK1/2).	Urocortins	0-9	mitogen-activated protein kinase 3	Homo sapiens	285-291
34351805-6	2021	Additionally, phospholipase-A2 inhibition, mitochondrial permeability transition pore (MPT-pore) blockade and suppression of apoptosis are involved in urocortin-elicited cardioprotection.	Urocortins	151-160	phospholipase A2 group IB	Homo sapiens	14-30
33564054-6	2021	Fifty-four memory candidate sites showed correlation between methylation and transcription, and the representative corresponding gene was UCN, which encodes urocortin.	Urocortins	157-166	urocortin	Homo sapiens	138-141
35219718-4	2022	In the present study we investigated in MCF7 human breast cancer cells the effect of urocortin onto mitogenic signaling via ERK1/2.	Urocortins	85-94	mitogen-activated protein kinase 3	Homo sapiens	124-130
34215021-3	2021	METHODS: We investigate CRF1 expression in the brainstem and the colonic response to 4th ventricle (4V) injection of CRF and urocortin (Ucn) 2 (3 microg/rat) in chronically cannulated male rats.	Urocortins	125-134	urocortin	Rattus norvegicus	136-139
32949605-0	2020	Urocortin participates in LPS-induced apoptosis of THP-1 macrophages via S1P-cPLA2 signaling pathway.	Urocortins	0-9	GLI family zinc finger 2	Homo sapiens	51-56
32949605-0	2020	Urocortin participates in LPS-induced apoptosis of THP-1 macrophages via S1P-cPLA2 signaling pathway.	Urocortins	0-9	phospholipase A2 group IVA	Homo sapiens	77-82
28802560-5	2017	Further, mice that sustained a juvenile TBI exhibited a significantly reduced activation of cFos in the urocortin-positive cells of the Edinger-Westphal nucleus in response to ethanol administration.	Urocortins	104-113	FBJ osteosarcoma oncogene	Mus musculus	92-96
31073117-0	2019	Urocortin Induces Phosphorylation of Distinct Residues of Signal Transducer and Activator of Transcription 3 (STAT3) via Different Signaling Pathways.	Urocortins	0-9	signal transducer and activator of transcription 3	Mus musculus	58-108
31073117-0	2019	Urocortin Induces Phosphorylation of Distinct Residues of Signal Transducer and Activator of Transcription 3 (STAT3) via Different Signaling Pathways.	Urocortins	0-9	signal transducer and activator of transcription 3	Mus musculus	110-115
31073117-6	2019	Urocortin treatment induced STAT3 phosphorylation at Y705 and S727 through transactivation of JAK2 in an IL-6-dependent manner, but had no effect on STAT1 activity.	Urocortins	0-9	signal transducer and activator of transcription 3	Mus musculus	28-33
31073117-6	2019	Urocortin treatment induced STAT3 phosphorylation at Y705 and S727 through transactivation of JAK2 in an IL-6-dependent manner, but had no effect on STAT1 activity.	Urocortins	0-9	Janus kinase 2	Mus musculus	94-98
31073117-6	2019	Urocortin treatment induced STAT3 phosphorylation at Y705 and S727 through transactivation of JAK2 in an IL-6-dependent manner, but had no effect on STAT1 activity.	Urocortins	0-9	interleukin 6	Mus musculus	105-109
31073117-7	2019	Kinase inhibition experiments revealed that urocortin induces STAT3 S727 phosphorylation through ERK1/2 and Y705 phosphorylation through Src tyrosine kinase.	Urocortins	44-53	signal transducer and activator of transcription 3	Mus musculus	62-67
31073117-7	2019	Kinase inhibition experiments revealed that urocortin induces STAT3 S727 phosphorylation through ERK1/2 and Y705 phosphorylation through Src tyrosine kinase.	Urocortins	44-53	mitogen-activated protein kinase 3	Mus musculus	97-103
27458591-3	2016	In vitro studies have evidenced that urocortin (UCN) and CRF provoke an increase in the contractility of the uterus which is induced by endometrial prostaglandin F2a.	Urocortins	37-46	urocortin	Homo sapiens	48-51
27832152-12	2016	Cardiomyocyte apoptosis was lower in the urocortin-treated group (39.9+-8.6 vs. 17.5+-4.6% of TUNEL positive nuclei, P<0.05) with significantly increased Akt, ERK and STAT-3 activation and phosphorylation in the myocardium (P<0.05).	Urocortins	41-50	AKT serine/threonine kinase 1	Rattus norvegicus	157-160
27832152-12	2016	Cardiomyocyte apoptosis was lower in the urocortin-treated group (39.9+-8.6 vs. 17.5+-4.6% of TUNEL positive nuclei, P<0.05) with significantly increased Akt, ERK and STAT-3 activation and phosphorylation in the myocardium (P<0.05).	Urocortins	41-50	Eph receptor B1	Rattus norvegicus	162-165
27832152-12	2016	Cardiomyocyte apoptosis was lower in the urocortin-treated group (39.9+-8.6 vs. 17.5+-4.6% of TUNEL positive nuclei, P<0.05) with significantly increased Akt, ERK and STAT-3 activation and phosphorylation in the myocardium (P<0.05).	Urocortins	41-50	signal transducer and activator of transcription 3	Rattus norvegicus	170-176
28698554-0	2017	Chondroprotection by urocortin involves blockade of the mechanosensitive ion channel Piezo1.	Urocortins	21-30	piezo type mechanosensitive ion channel component 1	Homo sapiens	85-91
27397599-9	2016	Urocortin I prevented indomethacin-induced enteropathy, and this effect was completely abrogated by the pretreatment with astressin 2B, a CRF2 receptor antagonist, but was not significantly affected by either adrenalectomy or the mifepristone pretreatment.	Urocortins	0-11	corticotropin releasing hormone receptor 2	Rattus norvegicus	138-142
26756093-8	2016	Blocking p300 efficiently suppressed the urocortin-induced Col4 expression in LX-2 cells and unveiled an apoptosis-inducing effect of urocortin.	Urocortins	41-50	E1A binding protein p300	Homo sapiens	9-13
26756093-8	2016	Blocking p300 efficiently suppressed the urocortin-induced Col4 expression in LX-2 cells and unveiled an apoptosis-inducing effect of urocortin.	Urocortins	134-143	E1A binding protein p300	Homo sapiens	9-13
26934363-11	2016	Moreover, inhibition of phosphorylation of Akt and GSK-3beta was also reversed by urocortin.	Urocortins	82-91	AKT serine/threonine kinase 1	Rattus norvegicus	43-46
26934363-11	2016	Moreover, inhibition of phosphorylation of Akt and GSK-3beta was also reversed by urocortin.	Urocortins	82-91	glycogen synthase kinase 3 beta	Rattus norvegicus	51-60
26780729-5	2016	To investigate the effect of stress hormone on zinc-induced cell death, neuroblastoma SH-SY5Y cells were pretreated with urocortin, a corticotropin releasing factor (CRF)-related peptide.	Urocortins	121-130	corticotropin releasing hormone	Homo sapiens	134-164
26780729-8	2016	Moreover, application of TRPM7 channel blockers and RNA interference of TRPM7 channel expression attenuated the zinc-induced cell death in urocortin-pretreated cells, indicating that TRPM7 channel may serve as a zinc influx pathway.	Urocortins	139-148	transient receptor potential cation channel subfamily M member 7	Homo sapiens	25-30
26780729-8	2016	Moreover, application of TRPM7 channel blockers and RNA interference of TRPM7 channel expression attenuated the zinc-induced cell death in urocortin-pretreated cells, indicating that TRPM7 channel may serve as a zinc influx pathway.	Urocortins	139-148	transient receptor potential cation channel subfamily M member 7	Homo sapiens	72-77
26780729-8	2016	Moreover, application of TRPM7 channel blockers and RNA interference of TRPM7 channel expression attenuated the zinc-induced cell death in urocortin-pretreated cells, indicating that TRPM7 channel may serve as a zinc influx pathway.	Urocortins	139-148	transient receptor potential cation channel subfamily M member 7	Homo sapiens	72-77
25712670-1	2015	BACKGROUND: Urocortin (UCN) is a newly identified vascular-active peptide that has been shown to reverse cardiovascular remodeling and improve left ventricular (LV) function.	Urocortins	12-21	urocortin	Rattus norvegicus	23-26
25904177-1	2015	The role of urocortin (UCN) is still ambiguous in human cancers.	Urocortins	12-21	urocortin	Homo sapiens	23-26
26138318-0	2015	Urocortin attenuates TGFbeta1-induced Snail1 and slug expressions: inhibitory role of Smad7 in Smad2/3 signaling in breast cancer cells.	Urocortins	0-9	transforming growth factor beta 1	Homo sapiens	21-29
26138318-0	2015	Urocortin attenuates TGFbeta1-induced Snail1 and slug expressions: inhibitory role of Smad7 in Smad2/3 signaling in breast cancer cells.	Urocortins	0-9	snail family transcriptional repressor 1	Homo sapiens	38-44
26138318-0	2015	Urocortin attenuates TGFbeta1-induced Snail1 and slug expressions: inhibitory role of Smad7 in Smad2/3 signaling in breast cancer cells.	Urocortins	0-9	snail family transcriptional repressor 2	Homo sapiens	49-53
26138318-0	2015	Urocortin attenuates TGFbeta1-induced Snail1 and slug expressions: inhibitory role of Smad7 in Smad2/3 signaling in breast cancer cells.	Urocortins	0-9	SMAD family member 7	Homo sapiens	86-91
26138318-0	2015	Urocortin attenuates TGFbeta1-induced Snail1 and slug expressions: inhibitory role of Smad7 in Smad2/3 signaling in breast cancer cells.	Urocortins	0-9	SMAD family member 2	Homo sapiens	95-102
26138318-4	2015	Our present data in MCF-7 and MDA-MB-231 cells showed that Urocortin (Ucn, a member of CRH family) inhibited TGFbeta1 signaling by reducing Smad2/3 activation and subsequent nuclear translocation through increasing Smad7 expression, leading to downregulation of Snail1 and Slug, the two EMT promoters.	Urocortins	59-68	urocortin	Homo sapiens	70-73
26138318-4	2015	Our present data in MCF-7 and MDA-MB-231 cells showed that Urocortin (Ucn, a member of CRH family) inhibited TGFbeta1 signaling by reducing Smad2/3 activation and subsequent nuclear translocation through increasing Smad7 expression, leading to downregulation of Snail1 and Slug, the two EMT promoters.	Urocortins	59-68	corticotropin releasing hormone	Homo sapiens	87-90
26138318-4	2015	Our present data in MCF-7 and MDA-MB-231 cells showed that Urocortin (Ucn, a member of CRH family) inhibited TGFbeta1 signaling by reducing Smad2/3 activation and subsequent nuclear translocation through increasing Smad7 expression, leading to downregulation of Snail1 and Slug, the two EMT promoters.	Urocortins	59-68	transforming growth factor beta 1	Homo sapiens	109-117
26138318-4	2015	Our present data in MCF-7 and MDA-MB-231 cells showed that Urocortin (Ucn, a member of CRH family) inhibited TGFbeta1 signaling by reducing Smad2/3 activation and subsequent nuclear translocation through increasing Smad7 expression, leading to downregulation of Snail1 and Slug, the two EMT promoters.	Urocortins	59-68	SMAD family member 2	Homo sapiens	140-147
26138318-4	2015	Our present data in MCF-7 and MDA-MB-231 cells showed that Urocortin (Ucn, a member of CRH family) inhibited TGFbeta1 signaling by reducing Smad2/3 activation and subsequent nuclear translocation through increasing Smad7 expression, leading to downregulation of Snail1 and Slug, the two EMT promoters.	Urocortins	59-68	SMAD family member 7	Homo sapiens	215-220
26138318-4	2015	Our present data in MCF-7 and MDA-MB-231 cells showed that Urocortin (Ucn, a member of CRH family) inhibited TGFbeta1 signaling by reducing Smad2/3 activation and subsequent nuclear translocation through increasing Smad7 expression, leading to downregulation of Snail1 and Slug, the two EMT promoters.	Urocortins	59-68	snail family transcriptional repressor 1	Homo sapiens	262-268
26138318-4	2015	Our present data in MCF-7 and MDA-MB-231 cells showed that Urocortin (Ucn, a member of CRH family) inhibited TGFbeta1 signaling by reducing Smad2/3 activation and subsequent nuclear translocation through increasing Smad7 expression, leading to downregulation of Snail1 and Slug, the two EMT promoters.	Urocortins	59-68	snail family transcriptional repressor 2	Homo sapiens	273-277
26260050-8	2015	Two other molecular ions specifically m/z 8100 and m/z 11,800 were also selected, corresponding to reported masses of urocortin precursor and thioredoxin, respectively.	Urocortins	118-127	thioredoxin	Homo sapiens	142-153
24954177-1	2014	OBJECTIVES: The present study investigated the cardioprotective role of urocortin (Ucn) and its relationship with protein kinase C (PKC)epsilon and PKCdelta in patients with (DMPs) and without (NDMPs) diabetes mellitus after on-pump cardiac surgery (OPCS).	Urocortins	72-81	urocortin	Homo sapiens	83-86
25464253-0	2015	Estrogen enhancement of SGK1 expression induced by urocortin contributes to its cardioprotection against ischemia/reperfusion insult.	Urocortins	51-60	serum/glucocorticoid regulated kinase 1	Homo sapiens	24-28
25667611-0	2015	Urocortin ameliorates diabetic cardiomyopathy in rats via the Akt/GSK-3beta signaling pathway.	Urocortins	0-9	AKT serine/threonine kinase 1	Rattus norvegicus	62-65
25667611-0	2015	Urocortin ameliorates diabetic cardiomyopathy in rats via the Akt/GSK-3beta signaling pathway.	Urocortins	0-9	glycogen synthase kinase 3 beta	Rattus norvegicus	66-75
25667611-13	2015	In addition, the inhibited phosphorylation of Akt and GSK-3beta was restored with urocortin administration.	Urocortins	82-91	AKT serine/threonine kinase 1	Rattus norvegicus	46-49
25667611-13	2015	In addition, the inhibited phosphorylation of Akt and GSK-3beta was restored with urocortin administration.	Urocortins	82-91	glycogen synthase kinase 3 beta	Rattus norvegicus	54-63
25667611-14	2015	However, all the effects of urocortin were eliminated with treatment of the corticotropin releasing factor receptor 2 antagonist, astressin.	Urocortins	28-37	corticotropin releasing hormone receptor 2	Rattus norvegicus	76-117
25667611-15	2015	Triciribine, an Akt inhibitor, partially eliminated the effects of urocortin on myocardial dysfunction, inflammation and cardiac fibrosis in the hearts of the diabetic rats.	Urocortins	67-76	AKT serine/threonine kinase 1	Rattus norvegicus	16-19
25265283-0	2014	Peripheral alpha2-beta1 adrenergic interactions mediate the ghrelin response to brain urocortin 1 in rats.	Urocortins	86-97	ghrelin and obestatin prepropeptide	Rattus norvegicus	60-67
24954177-1	2014	OBJECTIVES: The present study investigated the cardioprotective role of urocortin (Ucn) and its relationship with protein kinase C (PKC)epsilon and PKCdelta in patients with (DMPs) and without (NDMPs) diabetes mellitus after on-pump cardiac surgery (OPCS).	Urocortins	72-81	protein kinase C epsilon	Homo sapiens	132-143
24954177-1	2014	OBJECTIVES: The present study investigated the cardioprotective role of urocortin (Ucn) and its relationship with protein kinase C (PKC)epsilon and PKCdelta in patients with (DMPs) and without (NDMPs) diabetes mellitus after on-pump cardiac surgery (OPCS).	Urocortins	72-81	protein kinase C delta	Homo sapiens	148-156
25172671-3	2014	Urocortin (UCN) exhibits a powerful concentration-dependent vasodilatation effect in the utero-placental-fetal unit.	Urocortins	0-9	urocortin	Homo sapiens	11-14
24363440-0	2014	Urocortin increased endothelial ICAM1 by cPLA2-dependent NF-kappaB and PKA pathways in HUVECs.	Urocortins	0-9	intercellular adhesion molecule 1	Homo sapiens	32-37
24363440-0	2014	Urocortin increased endothelial ICAM1 by cPLA2-dependent NF-kappaB and PKA pathways in HUVECs.	Urocortins	0-9	phospholipase A2 group IVA	Homo sapiens	41-46
24363440-0	2014	Urocortin increased endothelial ICAM1 by cPLA2-dependent NF-kappaB and PKA pathways in HUVECs.	Urocortins	0-9	nuclear factor kappa B subunit 1	Homo sapiens	57-66
22946657-12	2013	The CRF(1) : RAMP2 complex resulted in enhanced elevation of intracellular calcium to CRF and urocortin 1 but not sauvagine.	Urocortins	94-105	receptor (calcitonin) activity modifying protein 2	Mus musculus	13-18
24069562-0	2013	The cardioprotective effects of urocortin are mediated via activation of the Src tyrosine kinase-STAT3 pathway.	Urocortins	32-41	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	77-80
24069562-0	2013	The cardioprotective effects of urocortin are mediated via activation of the Src tyrosine kinase-STAT3 pathway.	Urocortins	32-41	signal transducer and activator of transcription 3	Homo sapiens	97-102
24069562-1	2013	Src tyrosine kinase family was recently identified as a novel upstream modulator of MAP kinase subfamily, p42/p44, whose activation is required for urocortin (Ucn)-mediated cardioprotection.	Urocortins	148-157	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	0-3
24069562-1	2013	Src tyrosine kinase family was recently identified as a novel upstream modulator of MAP kinase subfamily, p42/p44, whose activation is required for urocortin (Ucn)-mediated cardioprotection.	Urocortins	148-157	cyclin dependent kinase 20	Homo sapiens	106-109
24069562-1	2013	Src tyrosine kinase family was recently identified as a novel upstream modulator of MAP kinase subfamily, p42/p44, whose activation is required for urocortin (Ucn)-mediated cardioprotection.	Urocortins	148-157	general transcription factor IIH subunit 2	Homo sapiens	110-113
24069562-1	2013	Src tyrosine kinase family was recently identified as a novel upstream modulator of MAP kinase subfamily, p42/p44, whose activation is required for urocortin (Ucn)-mediated cardioprotection.	Urocortins	159-162	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	0-3
24069562-1	2013	Src tyrosine kinase family was recently identified as a novel upstream modulator of MAP kinase subfamily, p42/p44, whose activation is required for urocortin (Ucn)-mediated cardioprotection.	Urocortins	159-162	cyclin dependent kinase 20	Homo sapiens	106-109
24069562-1	2013	Src tyrosine kinase family was recently identified as a novel upstream modulator of MAP kinase subfamily, p42/p44, whose activation is required for urocortin (Ucn)-mediated cardioprotection.	Urocortins	159-162	general transcription factor IIH subunit 2	Homo sapiens	110-113
23523745-1	2013	Rats treated with three daily urocortin 1 (UCN) injections into the basolateral amygdala (BLA; i.e., UCN/BLA-primed rats) develop prolonged anxiety-associated behavior and vulnerability to panic-like physiological responses (i.e., tachycardia, hypertension and tachypnea) following intravenous infusions of 0.5 M sodium lactate (NaLac, an ordinarily mild interoceptive stressor).	Urocortins	43-46	urocortin	Rattus norvegicus	30-41
23164543-6	2013	However, microinjection of the CRHR2 agonist, urocortin III, into the PVN did not affect anxiogenic behavior in the male offspring.	Urocortins	46-59	corticotropin releasing hormone receptor 2	Rattus norvegicus	31-36
23057965-9	2012	Urocortin (10 pM), an agonist of CRF receptors, increased cell survival in the presence of glutamate.	Urocortins	0-9	corticotropin releasing hormone receptor 1	Rattus norvegicus	33-46
22547117-5	2013	Application of CRF and urocortin (UCN) to cerebellar slice cultures increased the density of spines on PC signaling via CRF receptors (CRF-Rs) 1 and 2 and RhoA downregulation, although the structural phenotypes of the induced spines varied, suggesting that CRF-Rs differentially induce the outgrowth of functionally distinct populations of spines.	Urocortins	23-32	urocortin	Homo sapiens	34-37
22547117-5	2013	Application of CRF and urocortin (UCN) to cerebellar slice cultures increased the density of spines on PC signaling via CRF receptors (CRF-Rs) 1 and 2 and RhoA downregulation, although the structural phenotypes of the induced spines varied, suggesting that CRF-Rs differentially induce the outgrowth of functionally distinct populations of spines.	Urocortins	23-32	corticotropin releasing hormone receptor 1	Homo sapiens	135-150
22547117-5	2013	Application of CRF and urocortin (UCN) to cerebellar slice cultures increased the density of spines on PC signaling via CRF receptors (CRF-Rs) 1 and 2 and RhoA downregulation, although the structural phenotypes of the induced spines varied, suggesting that CRF-Rs differentially induce the outgrowth of functionally distinct populations of spines.	Urocortins	23-32	ras homolog family member A	Homo sapiens	155-159
23183626-0	2013	Intravenous injection of urocortin 1 induces a CRF2 mediated increase in circulating ghrelin and glucose levels through distinct mechanisms in rats.	Urocortins	25-36	corticotropin releasing hormone receptor 2	Rattus norvegicus	47-51
23183626-0	2013	Intravenous injection of urocortin 1 induces a CRF2 mediated increase in circulating ghrelin and glucose levels through distinct mechanisms in rats.	Urocortins	25-36	ghrelin and obestatin prepropeptide	Rattus norvegicus	85-92
22244812-1	2012	Urotensin II (UII) and urocortin (UCN) are potent contributors to the physiopathology of heart failure.	Urocortins	23-32	urocortin	Rattus norvegicus	34-37
22684850-1	2012	Urocortin (UCN) is a 40-amino-acid peptide and a member of the corticotropin-releasing hormone (CRH) family, which includes CRH, urotensin I, sauvagine, UCN2 and UCN3.	Urocortins	0-9	urocortin 2	Equus caballus	153-157
22684850-1	2012	Urocortin (UCN) is a 40-amino-acid peptide and a member of the corticotropin-releasing hormone (CRH) family, which includes CRH, urotensin I, sauvagine, UCN2 and UCN3.	Urocortins	0-9	urocortin 3	Equus caballus	162-166
22684850-1	2012	Urocortin (UCN) is a 40-amino-acid peptide and a member of the corticotropin-releasing hormone (CRH) family, which includes CRH, urotensin I, sauvagine, UCN2 and UCN3.	Urocortins	0-9	urocortin	Equus caballus	11-14
22684850-1	2012	Urocortin (UCN) is a 40-amino-acid peptide and a member of the corticotropin-releasing hormone (CRH) family, which includes CRH, urotensin I, sauvagine, UCN2 and UCN3.	Urocortins	0-9	corticoliberin	Equus caballus	63-94
22684850-1	2012	Urocortin (UCN) is a 40-amino-acid peptide and a member of the corticotropin-releasing hormone (CRH) family, which includes CRH, urotensin I, sauvagine, UCN2 and UCN3.	Urocortins	0-9	corticoliberin	Equus caballus	96-99
22684850-1	2012	Urocortin (UCN) is a 40-amino-acid peptide and a member of the corticotropin-releasing hormone (CRH) family, which includes CRH, urotensin I, sauvagine, UCN2 and UCN3.	Urocortins	0-9	corticoliberin	Equus caballus	124-127
21505854-0	2012	Urocortin-induced cardiomyocytes hypertrophy is associated with regulation of the GSK-3beta pathway.	Urocortins	0-9	glycogen synthase kinase 3 beta	Rattus norvegicus	82-91
22257737-2	2012	Urocortin (UCN), a novel anti-inflammatory neuropeptide, protects injured cardiomyocytes and dopaminergic neurons.	Urocortins	0-9	urocortin	Rattus norvegicus	11-14
20032050-0	2010	Corticotropin-releasing hormone receptor-1 in cerebral microvessels changes during development and influences urocortin transport across the blood-brain barrier.	Urocortins	110-119	corticotropin releasing hormone receptor 1	Mus musculus	0-42
22675352-3	2012	We have shown that urocortin 1 and urocortin 3 are endogenously synthesized in the myocardial cells of human heart and may act on CRF type 2 receptor (CRFR2) expressed in the heart.	Urocortins	19-30	corticotropin releasing hormone receptor 2	Homo sapiens	151-156
21123435-6	2011	CRH, urocortin (Ucn)-1, and cortagine, a selective CRH(1) agonist, all increased intracellular cAMP, and this concentration-dependent response was inhibited by CRH(1)-selective antagonist NBI-35965.	Urocortins	5-14	urocortin	Homo sapiens	16-19
21123435-6	2011	CRH, urocortin (Ucn)-1, and cortagine, a selective CRH(1) agonist, all increased intracellular cAMP, and this concentration-dependent response was inhibited by CRH(1)-selective antagonist NBI-35965.	Urocortins	5-14	corticotropin releasing hormone	Homo sapiens	51-54
21123435-6	2011	CRH, urocortin (Ucn)-1, and cortagine, a selective CRH(1) agonist, all increased intracellular cAMP, and this concentration-dependent response was inhibited by CRH(1)-selective antagonist NBI-35965.	Urocortins	5-14	corticotropin releasing hormone	Homo sapiens	51-54
20933497-4	2010	Moreover, we investigated whether the potent cardioprotective corticotropin-releasing hormone (CRH), urocortin, which had been less focused on non-apoptotic cell death, inhibits the ischemic myocyte death.	Urocortins	101-110	corticotropin releasing hormone	Rattus norvegicus	62-93
20933497-4	2010	Moreover, we investigated whether the potent cardioprotective corticotropin-releasing hormone (CRH), urocortin, which had been less focused on non-apoptotic cell death, inhibits the ischemic myocyte death.	Urocortins	101-110	corticotropin releasing hormone	Rattus norvegicus	95-98
20933497-6	2010	Urocortin could significantly suppress the expression and activity of iPLA2, resulting in preventing the ischemia-induced cell death.	Urocortins	0-9	phospholipase A2 group VI	Rattus norvegicus	70-75
20933497-7	2010	The survival-promoting effect of urocortin was abrogated by the CRH receptor antagonist astressin.	Urocortins	33-42	corticotropin releasing hormone	Rattus norvegicus	64-67
20416357-0	2010	Activation of Src protein tyrosine kinase plays an essential role in urocortin-mediated cardioprotection.	Urocortins	69-78	Rous sarcoma oncogene	Mus musculus	14-17
20416357-3	2010	Studies have also showed that the protective action of urocortin is mediated by the activation of ERK1/2.	Urocortins	55-64	mitogen-activated protein kinase 3	Mus musculus	98-104
20416357-4	2010	We discovered that a non-receptor tyrosine kinase, Src, is involved in the urocortin-induced activation of ERK1/2 in mouse atrial HL-1 myocytes.	Urocortins	75-84	Rous sarcoma oncogene	Mus musculus	51-54
20416357-4	2010	We discovered that a non-receptor tyrosine kinase, Src, is involved in the urocortin-induced activation of ERK1/2 in mouse atrial HL-1 myocytes.	Urocortins	75-84	mitogen-activated protein kinase 3	Mus musculus	107-113
20416357-5	2010	The selective Src family kinase inhibitor, PP2, reduced the urocortin-induced phosphorylation of ERK1/2, and so did the expression of a dominant-negative mutant of Src in transfected HL-1 cells.	Urocortins	60-69	Rous sarcoma oncogene	Mus musculus	14-17
20416357-5	2010	The selective Src family kinase inhibitor, PP2, reduced the urocortin-induced phosphorylation of ERK1/2, and so did the expression of a dominant-negative mutant of Src in transfected HL-1 cells.	Urocortins	60-69	neuropeptide Y receptor Y6	Mus musculus	43-46
20416357-5	2010	The selective Src family kinase inhibitor, PP2, reduced the urocortin-induced phosphorylation of ERK1/2, and so did the expression of a dominant-negative mutant of Src in transfected HL-1 cells.	Urocortins	60-69	mitogen-activated protein kinase 3	Mus musculus	97-103
20416357-5	2010	The selective Src family kinase inhibitor, PP2, reduced the urocortin-induced phosphorylation of ERK1/2, and so did the expression of a dominant-negative mutant of Src in transfected HL-1 cells.	Urocortins	60-69	Rous sarcoma oncogene	Mus musculus	164-167
20416357-6	2010	Inhibition of Src by PP2 also reduced urocortin"s protective effects in HL-1 cells after hypoxia/reoxygenation (H/R), as assessed by flow cytometry and caspase-3 activation assay.	Urocortins	38-47	Rous sarcoma oncogene	Mus musculus	14-17
20416357-6	2010	Inhibition of Src by PP2 also reduced urocortin"s protective effects in HL-1 cells after hypoxia/reoxygenation (H/R), as assessed by flow cytometry and caspase-3 activation assay.	Urocortins	38-47	neuropeptide Y receptor Y6	Mus musculus	21-24
20416357-6	2010	Inhibition of Src by PP2 also reduced urocortin"s protective effects in HL-1 cells after hypoxia/reoxygenation (H/R), as assessed by flow cytometry and caspase-3 activation assay.	Urocortins	38-47	caspase 3	Mus musculus	152-161
20416357-7	2010	Titration studies indicated that as little as 10(-8)M urocortin was sufficient to induce Src activation.	Urocortins	54-63	Rous sarcoma oncogene	Mus musculus	89-92
20416357-8	2010	Maximal phosphorylation/activation of Src and ERK1/2 were both detected after 5 min incubation with urocortin.	Urocortins	100-109	Rous sarcoma oncogene	Mus musculus	38-41
20416357-8	2010	Maximal phosphorylation/activation of Src and ERK1/2 were both detected after 5 min incubation with urocortin.	Urocortins	100-109	mitogen-activated protein kinase 3	Mus musculus	46-52
20416357-10	2010	Here we report for the first time that short-term treatment with urocortin causes rapid phosphorylation of Src, and that the urocortin-activated Src kinase serves as an upstream modulator of ERK1/2 activation, playing an essential role in urocortin-mediated cardioprotection.	Urocortins	65-74	Rous sarcoma oncogene	Mus musculus	107-110
20416357-10	2010	Here we report for the first time that short-term treatment with urocortin causes rapid phosphorylation of Src, and that the urocortin-activated Src kinase serves as an upstream modulator of ERK1/2 activation, playing an essential role in urocortin-mediated cardioprotection.	Urocortins	65-74	Rous sarcoma oncogene	Mus musculus	145-148
20416357-10	2010	Here we report for the first time that short-term treatment with urocortin causes rapid phosphorylation of Src, and that the urocortin-activated Src kinase serves as an upstream modulator of ERK1/2 activation, playing an essential role in urocortin-mediated cardioprotection.	Urocortins	125-134	Rous sarcoma oncogene	Mus musculus	145-148
20416357-10	2010	Here we report for the first time that short-term treatment with urocortin causes rapid phosphorylation of Src, and that the urocortin-activated Src kinase serves as an upstream modulator of ERK1/2 activation, playing an essential role in urocortin-mediated cardioprotection.	Urocortins	125-134	mitogen-activated protein kinase 3	Mus musculus	191-197
21736884-0	2012	The cannabinoid receptor CB1 inverse agonist AM251 potentiates the anxiogenic activity of urocortin I in the basolateral amygdala.	Urocortins	90-101	cannabinoid receptor 1	Rattus norvegicus	25-28
19875195-0	2011	Urocortin modulates dopaminergic neuronal survival via inhibition of glycogen synthase kinase-3beta and histone deacetylase.	Urocortins	0-9	glycogen synthase kinase 3 beta	Rattus norvegicus	69-99
20480172-1	2011	PURPOSES: In this study, we sought to establish the value of a new molecule, urocortin (Ucn), in the diagnosis of endometrioma and compare with Ca-125 to identify superiority of urocortin.	Urocortins	77-86	urocortin	Homo sapiens	88-91
20821057-1	2010	Recent studies have indicated that the corticotropin releasing hormone (CRF)-related peptide, urocortin, restores key indicators of damage in animal models for Parkinson"s disease (PD).	Urocortins	94-103	corticotropin releasing hormone	Homo sapiens	39-70
20821057-5	2010	The protective effect of urocortin involved the activation of CRF receptor type 1, resulting in the increase of cyclic AMP (cAMP) levels.	Urocortins	25-34	corticotropin releasing hormone receptor 1	Homo sapiens	62-81
20821057-7	2010	As the downstream of this signal pathway, urocortin promoted phosphorylation of both glycogen synthase kinase 3beta and extracellular signal-regulated kinases, which are known to promote cell survival.	Urocortins	42-51	glycogen synthase kinase 3 beta	Homo sapiens	85-115
19707872-0	2010	Urocortin prevents indomethacin-induced small intestinal lesions in rats through activation of CRF2 receptors.	Urocortins	0-9	corticotropin releasing hormone receptor 2	Rattus norvegicus	95-99
20032050-9	2010	Supported by previous findings of receptor-mediated endocytosis of urocortin, these results suggest that permeation of urocortin across the BBB is dependent on the level of CRHR1 expression in cerebral microvessels.	Urocortins	67-76	corticotropin releasing hormone receptor 1	Mus musculus	173-178
20032050-9	2010	Supported by previous findings of receptor-mediated endocytosis of urocortin, these results suggest that permeation of urocortin across the BBB is dependent on the level of CRHR1 expression in cerebral microvessels.	Urocortins	119-128	corticotropin releasing hormone receptor 1	Mus musculus	173-178
19572944-11	2009	CONCLUSION AND IMPLICATIONS: Urocortin exacerbated the hypercoagulable state and vasculitis in a model of TAO induced by sodium laurate in rats, via CRF(1)-receptors.	Urocortins	29-38	corticotropin releasing hormone receptor 1	Rattus norvegicus	149-155
20237592-1	2010	Our previous acute study on urocortin (Ucn) demonstrated that Ucn altered serum and tissue angiotensin-converting enzyme (ACE) activity in rats.	Urocortins	28-37	urocortin	Rattus norvegicus	39-42
20237592-1	2010	Our previous acute study on urocortin (Ucn) demonstrated that Ucn altered serum and tissue angiotensin-converting enzyme (ACE) activity in rats.	Urocortins	28-37	urocortin	Rattus norvegicus	62-65
20237592-1	2010	Our previous acute study on urocortin (Ucn) demonstrated that Ucn altered serum and tissue angiotensin-converting enzyme (ACE) activity in rats.	Urocortins	28-37	angiotensin I converting enzyme	Rattus norvegicus	122-125
20388944-3	2009	Several functional studies documented that peripheral injection of CRF or urocortin stimulates colonic transit, motility, Fos expression in myenteric neurons, and defecation through activation of CRF(1) receptors, whereas it decreases ileal contractility via CRF(2) receptors.	Urocortins	74-83	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	122-125
19729048-4	2009	The application of urocortin reversibly inhibited both VOCC and the frequency of DA release events via the activation of type-1 CRF receptor.	Urocortins	19-28	corticotropin releasing hormone receptor 1	Homo sapiens	121-140
19466989-10	2009	The secretion of VEGF induced by TGF-beta1 in mesangial cells was inhibited by urocortin 1 pretreatment.	Urocortins	79-90	vascular endothelial growth factor A	Rattus norvegicus	17-21
19466989-10	2009	The secretion of VEGF induced by TGF-beta1 in mesangial cells was inhibited by urocortin 1 pretreatment.	Urocortins	79-90	transforming growth factor, beta 1	Rattus norvegicus	33-42
19406492-1	2009	The small peptide urocortin (Ucn) has the ability to protect the heart by reducing cardiac cell loss during myocardial ischemia/reperfusion, and improving post-ischemic cardiac performance.	Urocortins	18-27	urocortin	Homo sapiens	29-32
19703147-0	2009	Urocortin increases IL-4 and IL-10 secretion and reverses LPS-induced TNF-alpha release from human trophoblast primary cells.	Urocortins	0-9	interleukin 4	Homo sapiens	20-24
19703147-0	2009	Urocortin increases IL-4 and IL-10 secretion and reverses LPS-induced TNF-alpha release from human trophoblast primary cells.	Urocortins	0-9	interleukin 10	Homo sapiens	29-34
19703147-0	2009	Urocortin increases IL-4 and IL-10 secretion and reverses LPS-induced TNF-alpha release from human trophoblast primary cells.	Urocortins	0-9	interferon regulatory factor 6	Homo sapiens	58-61
19703147-0	2009	Urocortin increases IL-4 and IL-10 secretion and reverses LPS-induced TNF-alpha release from human trophoblast primary cells.	Urocortins	0-9	tumor necrosis factor	Homo sapiens	70-79
19703147-4	2009	RESULTS: Urocortin treatment induced a significant and dose-dependent increase of IL-4 and IL-10, whereas it did not affect TNF-alpha secretion.	Urocortins	9-18	interleukin 4	Homo sapiens	82-86
19703147-4	2009	RESULTS: Urocortin treatment induced a significant and dose-dependent increase of IL-4 and IL-10, whereas it did not affect TNF-alpha secretion.	Urocortins	9-18	interleukin 10	Homo sapiens	91-96
19703147-6	2009	CONCLUSION: Urocortin stimulates IL-4 and IL-10 secretion and reverses LPS-induced TNF-alpha release from trophoblast cells through action on CRH-R2 receptors, suggesting that this peptide may play a possible role as an anti-inflammatory agent.	Urocortins	12-21	interleukin 4	Homo sapiens	33-37
19703147-6	2009	CONCLUSION: Urocortin stimulates IL-4 and IL-10 secretion and reverses LPS-induced TNF-alpha release from trophoblast cells through action on CRH-R2 receptors, suggesting that this peptide may play a possible role as an anti-inflammatory agent.	Urocortins	12-21	interleukin 10	Homo sapiens	42-47
19703147-6	2009	CONCLUSION: Urocortin stimulates IL-4 and IL-10 secretion and reverses LPS-induced TNF-alpha release from trophoblast cells through action on CRH-R2 receptors, suggesting that this peptide may play a possible role as an anti-inflammatory agent.	Urocortins	12-21	interferon regulatory factor 6	Homo sapiens	71-74
19703147-6	2009	CONCLUSION: Urocortin stimulates IL-4 and IL-10 secretion and reverses LPS-induced TNF-alpha release from trophoblast cells through action on CRH-R2 receptors, suggesting that this peptide may play a possible role as an anti-inflammatory agent.	Urocortins	12-21	tumor necrosis factor	Homo sapiens	83-92
19703147-6	2009	CONCLUSION: Urocortin stimulates IL-4 and IL-10 secretion and reverses LPS-induced TNF-alpha release from trophoblast cells through action on CRH-R2 receptors, suggesting that this peptide may play a possible role as an anti-inflammatory agent.	Urocortins	12-21	corticotropin releasing hormone receptor 2	Homo sapiens	142-148
19694731-0	2009	Urocortin induced expression of COX-2 and ICAM-1 via corticotrophin-releasing factor type 2 receptor in rat aortic endothelial cells.	Urocortins	0-9	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	32-37
19694731-0	2009	Urocortin induced expression of COX-2 and ICAM-1 via corticotrophin-releasing factor type 2 receptor in rat aortic endothelial cells.	Urocortins	0-9	intercellular adhesion molecule 1	Rattus norvegicus	42-48
19619932-6	2009	RESULTS: Amniotic fluid urocortin concentrations in the cases (0.50+/-0.07 ng/ml) (M+/-SD) were significantly lower (P<0.0001) than in the control group (0.90+/-0.26 ng/ml), while CRF concentrations did not differ between the cases (1.52+/-0.39 ng/ml) and control group (1.64+/-0.68 ng/ml).	Urocortins	24-33	MSD	Homo sapiens	83-89
19409200-8	2009	Confocal imaging showed a rich colocalization of CRHR1 with CRH or urocortin I (Ucn I), and CRHR2 with CRH or urocortin III (Ucn III) in the PVN, and CRHR1 with CRH in the LC in EPM-tested groups.	Urocortins	67-78	corticotropin releasing hormone receptor 1	Rattus norvegicus	49-54
19409200-8	2009	Confocal imaging showed a rich colocalization of CRHR1 with CRH or urocortin I (Ucn I), and CRHR2 with CRH or urocortin III (Ucn III) in the PVN, and CRHR1 with CRH in the LC in EPM-tested groups.	Urocortins	67-78	corticotropin releasing hormone	Rattus norvegicus	49-52
19026631-1	2009	We have recently observed that the corticotrophin releasing factor (CRF) related peptide urocortin reverses key features of nigrostriatal damage in two paradigms of Parkinson"s disease.	Urocortins	89-98	corticotropin releasing hormone	Rattus norvegicus	35-66
19026631-6	2009	The effects of urocortin were entirely blocked by the non-selective CRF receptor antagonist alpha-helical CRF as well as the selective CRF(1) antagonist NBI 27914 and were not replicated by the selective CRF(2) ligand urocortin III.	Urocortins	15-24	corticotropin releasing hormone receptor 1	Rattus norvegicus	135-140
19255503-8	2009	CONCLUSION: In PAE urocortin II interaction with CRFR2 caused a cAMP-dependent and Ca2+-related phoshorylation of ERK, Akt and p38 leading to eNOS activation.	Urocortins	19-31	AKT serine/threonine kinase 1	Sus scrofa	119-122
19008330-4	2009	Stimulation of the cells with CRH or urocortin (UCN) resulted in rapid, transient increases in the intracellular levels of cAMP that were completely blocked by the addition of alpha-helical CRH 9-41 or astressin, non-selective CRH receptor antagonists.	Urocortins	37-46	urocortin	Mus musculus	48-51
19008330-4	2009	Stimulation of the cells with CRH or urocortin (UCN) resulted in rapid, transient increases in the intracellular levels of cAMP that were completely blocked by the addition of alpha-helical CRH 9-41 or astressin, non-selective CRH receptor antagonists.	Urocortins	37-46	corticotropin releasing hormone	Mus musculus	190-193
19008330-4	2009	Stimulation of the cells with CRH or urocortin (UCN) resulted in rapid, transient increases in the intracellular levels of cAMP that were completely blocked by the addition of alpha-helical CRH 9-41 or astressin, non-selective CRH receptor antagonists.	Urocortins	37-46	corticotropin releasing hormone	Mus musculus	190-193
18775757-0	2008	Involvement of CRH receptors in urocortin-induced hyperthermia.	Urocortins	32-41	corticotropin releasing hormone	Rattus norvegicus	15-18
18804421-1	2008	Systemic administration of urocortin I (Ucn I), a member of the corticotrophin-releasing factor (CRF) peptide family, modulates cardiovascular system.	Urocortins	27-38	corticotropin releasing hormone	Rattus norvegicus	64-95
18775757-1	2008	The actions of individual corticotropin-releasing hormone (CRH) receptor (CRHR1 and CRHR2) were studied on the hyperthermia caused by urocortin 1, urocortin 2 and urocortin 3 in rats.	Urocortins	134-145	corticotropin releasing hormone	Rattus norvegicus	59-62
18775757-5	2008	CRH 9-41 and antalarmin, CRHR1 receptor antagonists, prevented the urocortin-induced increase in colon temperature while astressin 2B (CRHR2 receptor antagonist) was ineffective.	Urocortins	67-76	corticotropin releasing hormone	Rattus norvegicus	0-3
18775757-5	2008	CRH 9-41 and antalarmin, CRHR1 receptor antagonists, prevented the urocortin-induced increase in colon temperature while astressin 2B (CRHR2 receptor antagonist) was ineffective.	Urocortins	67-76	corticotropin releasing hormone receptor 1	Rattus norvegicus	25-30
18775757-5	2008	CRH 9-41 and antalarmin, CRHR1 receptor antagonists, prevented the urocortin-induced increase in colon temperature while astressin 2B (CRHR2 receptor antagonist) was ineffective.	Urocortins	67-76	corticotropin releasing hormone receptor 2	Rattus norvegicus	135-140
18587447-10	2008	Moreover, urocortin inhibited the overexpression of transforming growth factor-beta 1 and connective tissue growth factor in rat mesangial cells induced by 25 mM glucose.	Urocortins	10-19	transforming growth factor, beta 1	Rattus norvegicus	52-85
18587447-10	2008	Moreover, urocortin inhibited the overexpression of transforming growth factor-beta 1 and connective tissue growth factor in rat mesangial cells induced by 25 mM glucose.	Urocortins	10-19	cellular communication network factor 2	Rattus norvegicus	90-121
17898228-3	2007	The present studies addressed this question by examining the neuroanatomical, behavioral, and pharmacological mechanisms mediating decreases in feeding produced by the CRF1/CRF2 receptor agonist urocortin.	Urocortins	195-204	corticotropin releasing hormone receptor 1	Rattus norvegicus	168-172
17976162-4	2008	CRF(1)-preferring or non-selective agonists such as CRF, urocortin 1 (UCN1), and sauvagine stimulated cAMP production in Y79 to maximal responses of approximately 100 pmoles/10(5) cells, whereas the exclusive CRF2 receptor-selective agonists UCN2 and 3 stimulated cAMP production to maximal responses of approximately 25-30 pmoles/10(5) cells.	Urocortins	57-68	corticotropin releasing hormone receptor 1	Homo sapiens	0-5
17976162-4	2008	CRF(1)-preferring or non-selective agonists such as CRF, urocortin 1 (UCN1), and sauvagine stimulated cAMP production in Y79 to maximal responses of approximately 100 pmoles/10(5) cells, whereas the exclusive CRF2 receptor-selective agonists UCN2 and 3 stimulated cAMP production to maximal responses of approximately 25-30 pmoles/10(5) cells.	Urocortins	57-68	corticotropin releasing hormone receptor 2	Homo sapiens	209-213
17976162-4	2008	CRF(1)-preferring or non-selective agonists such as CRF, urocortin 1 (UCN1), and sauvagine stimulated cAMP production in Y79 to maximal responses of approximately 100 pmoles/10(5) cells, whereas the exclusive CRF2 receptor-selective agonists UCN2 and 3 stimulated cAMP production to maximal responses of approximately 25-30 pmoles/10(5) cells.	Urocortins	57-68	urocortin 2	Homo sapiens	242-252
17885217-0	2007	Role of Ca2+-independent phospholipase A2 and store-operated pathway in urocortin-induced vasodilatation of rat coronary artery.	Urocortins	72-81	phospholipase A2 group VI	Rattus norvegicus	8-41
17885217-2	2007	Here we demonstrate the role of store operated Ca2+ entry (SOCE) regulated by Ca2+-independent phospholipase A2 (iPLA2) in phenylephrine hydrochloride (PE)-induced vasoconstriction, and we present the first evidence that urocortin induces relaxation by the modulation of SOCE and iPLA2 in rat coronary artery.	Urocortins	221-230	phospholipase A2 group VI	Rattus norvegicus	78-111
17885217-2	2007	Here we demonstrate the role of store operated Ca2+ entry (SOCE) regulated by Ca2+-independent phospholipase A2 (iPLA2) in phenylephrine hydrochloride (PE)-induced vasoconstriction, and we present the first evidence that urocortin induces relaxation by the modulation of SOCE and iPLA2 in rat coronary artery.	Urocortins	221-230	phospholipase A2 group VI	Rattus norvegicus	113-118
17885217-4	2007	We show in coronary smooth muscle cells (SMCs) that urocortin inhibits iPLA2 activation, a crucial step for SOC channel activation, and prevents Ca2+ influx evoked by the emptying of the stores via a cAMP and protein kinase A (PKA)-dependent mechanism.	Urocortins	52-61	phospholipase A2 group VI	Rattus norvegicus	71-76
17885217-4	2007	We show in coronary smooth muscle cells (SMCs) that urocortin inhibits iPLA2 activation, a crucial step for SOC channel activation, and prevents Ca2+ influx evoked by the emptying of the stores via a cAMP and protein kinase A (PKA)-dependent mechanism.	Urocortins	52-61	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	209-225
17885217-4	2007	We show in coronary smooth muscle cells (SMCs) that urocortin inhibits iPLA2 activation, a crucial step for SOC channel activation, and prevents Ca2+ influx evoked by the emptying of the stores via a cAMP and protein kinase A (PKA)-dependent mechanism.	Urocortins	52-61	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	227-230
17885217-6	2007	Furthermore, we report that long treatment with urocortin downregulates iPLA2 mRNA and proteins expression in rat coronary smooth muscle cells.	Urocortins	48-57	phospholipase A2 group VI	Rattus norvegicus	72-77
17885217-7	2007	In summary, we propose a new mechanism of vasodilatation by urocortin which involves the regulation of iPLA2 and SOCE via the stimulation of a cAMP/PKA-dependent signal transduction cascade in rat coronary artery.	Urocortins	60-69	phospholipase A2 group VI	Rattus norvegicus	103-108
17885217-7	2007	In summary, we propose a new mechanism of vasodilatation by urocortin which involves the regulation of iPLA2 and SOCE via the stimulation of a cAMP/PKA-dependent signal transduction cascade in rat coronary artery.	Urocortins	60-69	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	148-151
18385521-5	2008	The therapeutic effect of VIP and urocortin was accompanied by a decrease in systemic levels of HMGB1.	Urocortins	34-43	high mobility group box 1	Mus musculus	96-101
18385521-6	2008	In addition, administration of recombinant HMGB1 completely reversed the protective effect of VIP and urocortin in experimental sepsis.	Urocortins	102-111	high mobility group box 1	Mus musculus	43-48
18164138-3	2008	Perioculomotor urocortin-containing neurons (pIIIu), also known as the non-preganglionic Edinger-Westphal nucleus, are the major source of Ucn1 in the brain and are known to innervate the lateral septum.	Urocortins	15-24	urocortin	Mus musculus	139-143
18209484-2	2008	The purpose of this study was to investigate the effect of urocortin (UCN), a 40-amino-acid CRF family peptide, on degranulation and intracellular calcium of rat lung mast cells.	Urocortins	59-68	urocortin	Rattus norvegicus	70-73
17898228-3	2007	The present studies addressed this question by examining the neuroanatomical, behavioral, and pharmacological mechanisms mediating decreases in feeding produced by the CRF1/CRF2 receptor agonist urocortin.	Urocortins	195-204	corticotropin releasing hormone receptor 2	Rattus norvegicus	173-177
17346851-0	2007	Inhibitory effects of glucocorticoids on urocortin-mediated increases in interleukin-6 gene expression in rat aortic smooth muscle cells.	Urocortins	41-50	interleukin 6	Rattus norvegicus	73-86
17437087-9	2007	CRF(6-33), which competes for the CRF binding site on CRF-BP, attenuated the effects of CRF or urocortin I on VTA glutamate and dopamine release and on reinstatement of cocaine seeking.	Urocortins	95-106	corticotropin releasing hormone binding protein	Rattus norvegicus	54-60
17659087-1	2007	We have recently observed that the corticotrophin releasing hormone (CRF) related peptide urocortin (UCN) reverses key features of nigrostriatal damage in the hemiparkinsonian 6-hydroxydopamine lesioned rat.	Urocortins	90-99	urocortin	Rattus norvegicus	101-104
17506983-5	2007	The effect of urocortin was abolished by specific CRF-R1 antagonist and was mimicked by protein kinase C (PKC) activator, phorbol 12-myristate 13-acetate.	Urocortins	14-23	corticotropin releasing hormone receptor 1	Mus musculus	50-56
17506983-7	2007	These results suggest that urocortin modulates T-type Ca(2+) channel by interacting with CRF-R1 via the activation of PKC signal pathway in MN9D cells.	Urocortins	27-36	corticotropin releasing hormone receptor 1	Mus musculus	89-95
17650114-1	2007	The potential neuroprotective action of the corticotrophin-releasing factor-related peptide urocortin (UCN) was investigated in the rat 6-hydroxydopamine (6-OHDA) and lipopolysaccharide (LPS) paradigms of Parkinson"s disease.	Urocortins	92-101	urocortin	Rattus norvegicus	103-106
17265488-0	2007	Therapeutic effect of urocortin on collagen-induced arthritis by down-regulation of inflammatory and Th1 responses and induction of regulatory T cells.	Urocortins	22-31	negative elongation factor complex member C/D	Homo sapiens	101-104
17170072-10	2007	Despite the substantial intracellular degradation of endocytosed urocortin in cells overexpressing either CRHR1 or CRHR2, intact urocortin could be exocytosed during the 1-h study interval.	Urocortins	65-74	corticotropin releasing hormone receptor 1	Homo sapiens	106-111
17170072-10	2007	Despite the substantial intracellular degradation of endocytosed urocortin in cells overexpressing either CRHR1 or CRHR2, intact urocortin could be exocytosed during the 1-h study interval.	Urocortins	65-74	corticotropin releasing hormone receptor 2	Homo sapiens	115-120
17326013-5	2007	Urocortin (Uct), urotensin and sauvagine are recently described members of the family of structurally related CRH-like peptides, whereas Uct shares a 45% homology with CRH.	Urocortins	0-9	urocortin	Homo sapiens	11-14
17326013-5	2007	Urocortin (Uct), urotensin and sauvagine are recently described members of the family of structurally related CRH-like peptides, whereas Uct shares a 45% homology with CRH.	Urocortins	0-9	corticotropin releasing hormone	Homo sapiens	110-113
17952632-0	2007	Unexpected amplification of leptin-induced Stat3 signaling by urocortin: implications for obesity.	Urocortins	62-71	leptin	Homo sapiens	28-34
16698078-1	2007	Urocortin (UCN) is a 40 amino acid peptide which is closely related to corticotropin-releasing hormone and binds with high affinity to both CRH type 1 and type 2 receptors.	Urocortins	0-9	urocortin	Homo sapiens	11-14
16698078-1	2007	Urocortin (UCN) is a 40 amino acid peptide which is closely related to corticotropin-releasing hormone and binds with high affinity to both CRH type 1 and type 2 receptors.	Urocortins	0-9	corticotropin releasing hormone	Homo sapiens	71-102
17478891-9	2007	In MDCK cells overexpressing CRHR2, leptin facilitated urocortin uptake, whereas ObRa coexpression did not exert an additional effect.	Urocortins	55-64	corticotropin releasing hormone receptor 2	Canis lupus familiaris	29-34
17952632-0	2007	Unexpected amplification of leptin-induced Stat3 signaling by urocortin: implications for obesity.	Urocortins	62-71	signal transducer and activator of transcription 3	Homo sapiens	43-48
17478891-9	2007	In MDCK cells overexpressing CRHR2, leptin facilitated urocortin uptake, whereas ObRa coexpression did not exert an additional effect.	Urocortins	55-64	leptin	Canis lupus familiaris	36-42
17952632-3	2007	After injection into the hypothalamus, urocortin can stimulate the release of leptin in the periphery.	Urocortins	39-48	leptin	Homo sapiens	78-84
17952632-8	2007	Urocortin induced significant Stat3 but not Stat1 activation, mediated by either CRHR1 or CRHR2.	Urocortins	0-9	signal transducer and activator of transcription 3	Homo sapiens	30-35
17952632-8	2007	Urocortin induced significant Stat3 but not Stat1 activation, mediated by either CRHR1 or CRHR2.	Urocortins	0-9	corticotropin releasing hormone receptor 1	Homo sapiens	81-86
17952632-8	2007	Urocortin induced significant Stat3 but not Stat1 activation, mediated by either CRHR1 or CRHR2.	Urocortins	0-9	corticotropin releasing hormone receptor 2	Homo sapiens	90-95
17952632-9	2007	Leptin signaling by ObRb caused a large increase of both Stat1 and Stat3, and this was significantly potentiated by the addition of urocortin, being more robust for Stat3 than Stat1.	Urocortins	132-141	leptin	Homo sapiens	0-6
17952632-9	2007	Leptin signaling by ObRb caused a large increase of both Stat1 and Stat3, and this was significantly potentiated by the addition of urocortin, being more robust for Stat3 than Stat1.	Urocortins	132-141	signal transducer and activator of transcription 1	Homo sapiens	57-62
17952632-9	2007	Leptin signaling by ObRb caused a large increase of both Stat1 and Stat3, and this was significantly potentiated by the addition of urocortin, being more robust for Stat3 than Stat1.	Urocortins	132-141	signal transducer and activator of transcription 3	Homo sapiens	67-72
17952632-9	2007	Leptin signaling by ObRb caused a large increase of both Stat1 and Stat3, and this was significantly potentiated by the addition of urocortin, being more robust for Stat3 than Stat1.	Urocortins	132-141	signal transducer and activator of transcription 3	Homo sapiens	165-170
17952632-9	2007	Leptin signaling by ObRb caused a large increase of both Stat1 and Stat3, and this was significantly potentiated by the addition of urocortin, being more robust for Stat3 than Stat1.	Urocortins	132-141	signal transducer and activator of transcription 1	Homo sapiens	176-181
17952632-11	2007	By unexpectedly potentiating leptin signaling through Stat, urocortin amplifies the cellular response of leptin.	Urocortins	60-69	leptin	Homo sapiens	29-35
17952632-11	2007	By unexpectedly potentiating leptin signaling through Stat, urocortin amplifies the cellular response of leptin.	Urocortins	60-69	leptin	Homo sapiens	105-111
17952632-12	2007	This novel phenomenon suggests that urocortin can play an important compensatory role during leptin resistance in obesity.	Urocortins	36-45	leptin	Homo sapiens	93-99
17131811-0	2006	[Urocortin decreases phosphorylation of MYPT1 and increases the myosin phosphatase activity via elevation of the intracellular level of cAMP].	Urocortins	1-10	protein phosphatase 1, regulatory subunit 12A	Mus musculus	40-45
16959871-1	2006	In most target cells, activation of the type 1 CRH receptor (CRH-R1) by CRH or urocortin (UCN I) leads to stimulation of the Gs-protein/adenylyl cyclase/protein kinase A cascade.	Urocortins	79-88	corticotropin releasing hormone	Homo sapiens	47-50
16959871-1	2006	In most target cells, activation of the type 1 CRH receptor (CRH-R1) by CRH or urocortin (UCN I) leads to stimulation of the Gs-protein/adenylyl cyclase/protein kinase A cascade.	Urocortins	79-88	corticotropin releasing hormone receptor 1	Homo sapiens	61-67
16959871-1	2006	In most target cells, activation of the type 1 CRH receptor (CRH-R1) by CRH or urocortin (UCN I) leads to stimulation of the Gs-protein/adenylyl cyclase/protein kinase A cascade.	Urocortins	79-88	corticotropin releasing hormone	Homo sapiens	61-64
16959871-1	2006	In most target cells, activation of the type 1 CRH receptor (CRH-R1) by CRH or urocortin (UCN I) leads to stimulation of the Gs-protein/adenylyl cyclase/protein kinase A cascade.	Urocortins	79-88	urocortin 2	Homo sapiens	90-95
16965298-2	2006	Because both CRF and urocortin 1 bind with high affinity to CRF receptor type 1 (CRF1) in mammals and Xenopus laevis, one of the purposes of the present study was to identify the sites of action of CRF and urocortin 1 in the Xenopus brain and pituitary gland.	Urocortins	21-32	corticotropin releasing hormone receptor 1, gene 2 S homeolog	Xenopus laevis	81-85
16965298-6	2006	The optical density of the CRF1 mRNA hybridisation signal in the intermediate lobe of the pituitary gland is 59.4% stronger in white-adapted animals than in black-adapted ones, supporting the hypothesis that the environmental light condition controls CRF1 mRNA expression in melanotroph cells of X. laevis, a mechanism likely to be responsible for CRF- and/or urocortin 1-stimulated secretion of alpha-MSH.	Urocortins	360-371	corticotropin releasing hormone receptor 1, gene 2 S homeolog	Xenopus laevis	27-31
17131811-0	2006	[Urocortin decreases phosphorylation of MYPT1 and increases the myosin phosphatase activity via elevation of the intracellular level of cAMP].	Urocortins	1-10	cathelicidin antimicrobial peptide	Mus musculus	136-141
17131811-8	2006	In permeabilized mouse tail arteries, treatment with 100 nM urocortin was associated with dephosphorylation of MLC20(Ser19) and MYPT1(Thr696/Thr850).	Urocortins	60-69	myosin, light polypeptide 9, regulatory	Mus musculus	111-116
17131811-8	2006	In permeabilized mouse tail arteries, treatment with 100 nM urocortin was associated with dephosphorylation of MLC20(Ser19) and MYPT1(Thr696/Thr850).	Urocortins	60-69	protein phosphatase 1, regulatory subunit 12A	Mus musculus	128-133
16650509-4	2006	Urocortin 1 caused a dose-related increase in colon temperature, maximal action being observed at a dose of 2 microg with the maximal increase in body temperature at 4 h. Noraminophenazone prevented the urocortin-induced increase in colon temperature and attenuated the already existing elevated body temperature.	Urocortins	203-212	urocortin	Rattus norvegicus	0-9
16174714-0	2005	Corticotropin-releasing hormone and urocortin induce secretion of matrix metalloproteinase-9 (MMP-9) without change in tissue inhibitors of MMP-1 by cultured cells from human placenta and fetal membranes.	Urocortins	36-45	matrix metallopeptidase 9	Homo sapiens	66-92
16697404-0	2006	Urocortin inhibits Beclin1-mediated autophagic cell death in cardiac myocytes exposed to ischaemia/reperfusion injury.	Urocortins	0-9	beclin 1	Rattus norvegicus	19-26
16697404-5	2006	The inhibition of autophagy by urocortin is mediated in part by inhibition of Beclin1 expression, an effect which is mediated by activation of the PI3 kinase/Akt pathway but which does not involve activation of p42/p44 MAPK.	Urocortins	31-40	beclin 1	Rattus norvegicus	78-85
16697404-5	2006	The inhibition of autophagy by urocortin is mediated in part by inhibition of Beclin1 expression, an effect which is mediated by activation of the PI3 kinase/Akt pathway but which does not involve activation of p42/p44 MAPK.	Urocortins	31-40	AKT serine/threonine kinase 1	Rattus norvegicus	158-161
16697404-5	2006	The inhibition of autophagy by urocortin is mediated in part by inhibition of Beclin1 expression, an effect which is mediated by activation of the PI3 kinase/Akt pathway but which does not involve activation of p42/p44 MAPK.	Urocortins	31-40	mitogen activated protein kinase 3	Rattus norvegicus	215-223
16574904-8	2006	The effect of urocortin on MLC20Ser19 and MYPT1 phosphorylation was blocked by Rp-8-CPT-cAMPS and mimicked by Sp-5,6-DCl-cBIMPS.	Urocortins	14-23	myosin, light polypeptide 9, regulatory	Mus musculus	27-32
16574904-8	2006	The effect of urocortin on MLC20Ser19 and MYPT1 phosphorylation was blocked by Rp-8-CPT-cAMPS and mimicked by Sp-5,6-DCl-cBIMPS.	Urocortins	14-23	protein phosphatase 1, regulatory subunit 12A	Mus musculus	42-47
16574904-9	2006	In summary, these results provide evidence that Ca(2+)-independent relaxation by urocortin can be attributed to a cAMP-mediated increased activity of SMPP-1M which at least in part is attributable to a decrease in the inhibitory phosphorylation of MYPT1.	Urocortins	81-90	protein phosphatase 1, regulatory subunit 12A	Mus musculus	248-253
16753930-5	2006	The current study investigates the behavioral effects in rodents when NPY is injected directly into the BLA prior to the pharmacological stressor, urocortin I (Ucn; a CRF receptor agonist) or the emotional stressor, restraint.	Urocortins	160-163	neuropeptide Y	Rattus norvegicus	70-73
16210362-5	2006	The effect of CRH in directly stimulating thermogenesis in skeletal muscle underscores a potentially important peripheral role for the CRH/urocortin system in the control of thermogenesis in this tissue, in its protection against excessive intramyocellular lipid storage, and hence against skeletal muscle lipotoxicity and insulin resistance.	Urocortins	139-148	corticotropin releasing hormone	Mus musculus	14-17
16488545-0	2006	Injections of urocortin 1 into the basolateral amygdala induce anxiety-like behavior and c-Fos expression in brainstem serotonergic neurons.	Urocortins	14-25	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	89-94
16488667-1	2006	We investigated the relationship between urocortin and the activity of angiotensin-converting enzyme (ACE), which plays a key role in producing the potent vasoconstrictor angiotensin II (Ang II).	Urocortins	41-50	angiotensin I converting enzyme	Rattus norvegicus	102-105
16488667-1	2006	We investigated the relationship between urocortin and the activity of angiotensin-converting enzyme (ACE), which plays a key role in producing the potent vasoconstrictor angiotensin II (Ang II).	Urocortins	41-50	angiotensinogen	Rattus norvegicus	171-185
16488667-1	2006	We investigated the relationship between urocortin and the activity of angiotensin-converting enzyme (ACE), which plays a key role in producing the potent vasoconstrictor angiotensin II (Ang II).	Urocortins	41-50	angiotensinogen	Rattus norvegicus	187-193
16488667-4	2006	Immunofluorescence studies were also preformed to evaluate the effect of urocortin on ACE in cultured rat aortic endothelial cells (RAECs).	Urocortins	73-82	angiotensin I converting enzyme	Rattus norvegicus	86-89
16488667-6	2006	The prolonged administration of urocortin enhanced tissue ACE activity but the serum ACE level remained low.	Urocortins	32-41	angiotensin I converting enzyme	Rattus norvegicus	58-61
16488667-8	2006	Immunofluorescence studies also demonstrated an increase of ACE intensity in RAECs exposed to urocortin for 72 h. Corticotropin-releasing factor (CRF) receptor blocker, astressin, abolished the effects of urocortin.	Urocortins	94-103	angiotensin I converting enzyme	Rattus norvegicus	60-63
16488667-8	2006	Immunofluorescence studies also demonstrated an increase of ACE intensity in RAECs exposed to urocortin for 72 h. Corticotropin-releasing factor (CRF) receptor blocker, astressin, abolished the effects of urocortin.	Urocortins	205-214	angiotensin I converting enzyme	Rattus norvegicus	60-63
16488667-9	2006	Extracellular signal-regulated kinase 1/2 (ERK1/2) pathway blocker, PD98059, also markedly inhibited these effects, suggesting urocortin affects the activity of ACE through the ERK1/2 pathway in rats.	Urocortins	127-136	mitogen activated protein kinase 3	Rattus norvegicus	0-41
16488667-9	2006	Extracellular signal-regulated kinase 1/2 (ERK1/2) pathway blocker, PD98059, also markedly inhibited these effects, suggesting urocortin affects the activity of ACE through the ERK1/2 pathway in rats.	Urocortins	127-136	mitogen activated protein kinase 3	Rattus norvegicus	43-49
16488667-9	2006	Extracellular signal-regulated kinase 1/2 (ERK1/2) pathway blocker, PD98059, also markedly inhibited these effects, suggesting urocortin affects the activity of ACE through the ERK1/2 pathway in rats.	Urocortins	127-136	angiotensin I converting enzyme	Rattus norvegicus	161-164
16488667-9	2006	Extracellular signal-regulated kinase 1/2 (ERK1/2) pathway blocker, PD98059, also markedly inhibited these effects, suggesting urocortin affects the activity of ACE through the ERK1/2 pathway in rats.	Urocortins	127-136	mitogen activated protein kinase 3	Rattus norvegicus	177-183
16488667-11	2006	Thus, the changes of the ACE activity and its production of Ang II may play a role in the vasodilatory property of urocortin.	Urocortins	115-124	angiotensin I converting enzyme	Rattus norvegicus	25-28
16488667-11	2006	Thus, the changes of the ACE activity and its production of Ang II may play a role in the vasodilatory property of urocortin.	Urocortins	115-124	angiotensinogen	Rattus norvegicus	60-66
16933022-4	2006	This suggests that urocortin relaxes blood vessels via cAMP-mediated dephosphorylation of MLC20.	Urocortins	19-28	myosin light chain 12B	Rattus norvegicus	90-95
16174714-0	2005	Corticotropin-releasing hormone and urocortin induce secretion of matrix metalloproteinase-9 (MMP-9) without change in tissue inhibitors of MMP-1 by cultured cells from human placenta and fetal membranes.	Urocortins	36-45	matrix metallopeptidase 9	Homo sapiens	94-99
16174714-6	2005	Antalarmin (a CRH receptor type 1 antagonist) significantly blocked CRH- and Ucn-induced pro-MMP-9 secretion from three cell types (P < 0.01, compared with treatment with CRH and Ucn alone, respectively).	Urocortins	77-80	corticotropin releasing hormone	Homo sapiens	14-17
16174714-6	2005	Antalarmin (a CRH receptor type 1 antagonist) significantly blocked CRH- and Ucn-induced pro-MMP-9 secretion from three cell types (P < 0.01, compared with treatment with CRH and Ucn alone, respectively).	Urocortins	77-80	matrix metallopeptidase 9	Homo sapiens	93-98
16174714-7	2005	Antisauvagine 30 (a CRH receptor type 2 antagonist) resulted in a significant reduction in CRH- and Ucn-induced secretion from chorionic trophoblast cells (P < 0.05) and syncytiotrophoblast cells (P < 0.01) compared with treatment with CRH and Ucn alone, respectively, but had no significant effect on amniotic epithelial cells.	Urocortins	100-103	corticotropin releasing hormone	Homo sapiens	20-23
15458766-1	2004	The newly isolated peptide, urocortin (UCN) has been found to have potent cardioprotective effects.	Urocortins	28-37	urocortin	Rattus norvegicus	39-42
15821006-8	2005	CONCLUSION: These data suggest that the endogenous urocortin peptides contribute to the suppression of vascular tone and renin-angiotensin-aldosterone/endothelin activation in HF and thus, play a protective compensatory role in this disorder.	Urocortins	51-60	renin	Ovis aries	121-126
15764590-0	2005	Cardioprotection mediated by urocortin is dependent on PKCepsilon activation.	Urocortins	29-38	protein kinase C, epsilon	Rattus norvegicus	55-65
15764590-1	2005	Urocortin (Ucn) is an endogenous cardioprotective agent that protects against the damaging effects of ischemia and reperfusion injury in vitro and in vivo.	Urocortins	0-9	urocortin	Rattus norvegicus	11-14
16300406-0	2005	Photoaffinity cross-linking of the corticotropin-releasing factor receptor type 1 with photoreactive urocortin analogues.	Urocortins	101-110	corticotropin releasing hormone	Homo sapiens	35-65
16300406-3	2005	Here, we identified by photoaffinity cross-linking using p-benzoyl-l-phenylalanine (Bpa) analogues of urocortin (Ucn) the most affine CRF receptor agonist, interaction domains of CRF(1) receptor with Bpa residues at exclusive positions.	Urocortins	102-111	urocortin	Homo sapiens	113-116
15961410-1	2005	AIMS: To investigate the subacute effects of a sustained intravenous infusion of urocortin-I (Ucn-I) in experimental heart failure (HF).	Urocortins	81-92	urocortin	Ovis aries	94-97
16054139-0	2005	Urocortin 1 and Urocortin 2 induce macrophage apoptosis via CRFR2.	Urocortins	0-11	corticotropin releasing hormone receptor 2	Homo sapiens	60-65
15911134-5	2005	Moreover, alpha-helical CRF-(9-41), a more specific antagonist of CRF-R2 than CRF-R1 and the adenylate cyclase inhibitor SQ22536, inhibited the urocortin-induced increase in the level of cAMP.	Urocortins	144-153	corticotropin releasing hormone receptor 2	Rattus norvegicus	66-72
15911134-5	2005	Moreover, alpha-helical CRF-(9-41), a more specific antagonist of CRF-R2 than CRF-R1 and the adenylate cyclase inhibitor SQ22536, inhibited the urocortin-induced increase in the level of cAMP.	Urocortins	144-153	corticotropin releasing hormone receptor 1	Rattus norvegicus	78-84
15911134-10	2005	In conclusion, we have demonstrated that urocortin stimulates catecholamine biosynthesis via the cAMP/protein kinase A pathway in PC12 cells, where both urocortin and its receptor, CRF-R2, are expressed.	Urocortins	41-50	corticotropin releasing hormone receptor 2	Rattus norvegicus	181-187
15806110-7	2005	5 These results suggest that urocortin may protect coronary endothelial function during I-R by activation of PKC.	Urocortins	29-38	protein kinase C, gamma	Rattus norvegicus	109-112
16049545-1	2005	The aim of this study was to investigate the effects of urocortin (UCN) on oxidative stress and the mechanisms of urocortin on ischemia-reperfusion injury in vivo in the rat model.	Urocortins	56-65	urocortin	Rattus norvegicus	67-70
15528398-7	2004	In the case of estrous behavior, the best available evidence suggests that the inhibitory NPY/CA system acts primarily via CRH or urocortin projections to various forebrain loci that control sexual receptivity.	Urocortins	130-139	neuropeptide Y	Homo sapiens	90-93
15319360-2	2004	New evidence indicates that urocortin (UCN), the putative agonist for the CRF type 2 receptor, has selective cardiovascular actions.	Urocortins	28-37	urocortin	Ovis aries	39-42
15256268-8	2004	Astressin (100-500 nM), a corticotropin-releasing factor (CRF) receptor antagonist and KT5720, a protein kinase A (PKA) inhibitor reduced urocortin-induced relaxation.	Urocortins	138-147	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	97-113
15320777-7	2004	Urocortin-mediated cardioprotection involves several mechanisms, including increased expression of Kir6.1 K(ATP) channels and HSP90, although other as yet poorly understood mechanisms have also been implicated.	Urocortins	0-9	potassium inwardly rectifying channel subfamily J member 8	Homo sapiens	99-105
15320777-7	2004	Urocortin-mediated cardioprotection involves several mechanisms, including increased expression of Kir6.1 K(ATP) channels and HSP90, although other as yet poorly understood mechanisms have also been implicated.	Urocortins	0-9	heat shock protein 90 alpha family class A member 1	Homo sapiens	126-131
15476941-1	2004	Urocortin, a 40 amino acid peptide, is a corticotropin-releasing factor (CRF) related peptide, and can bind to all three types of CRF receptors (CRF type 1, type 2a and type 2b receptors) with higher affinities for these receptors than CRF.	Urocortins	0-9	corticotropin releasing hormone	Homo sapiens	41-71
15256268-8	2004	Astressin (100-500 nM), a corticotropin-releasing factor (CRF) receptor antagonist and KT5720, a protein kinase A (PKA) inhibitor reduced urocortin-induced relaxation.	Urocortins	138-147	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	115-118
15256268-13	2004	Our results show that urocortin relaxed rat pulmonary arteries via CRF receptor-mediated and PKA-dependent but endothelium/NO or voltage-gated Ca2+ channel-independent mechanisms.	Urocortins	22-31	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	93-96
15358201-2	2004	An ATP sensitive inwardly rectifying potassium channel, Katp (Kir6.1), the enzyme calcium independent phospholipase A2 (iPLA2), and protein kinase C epsilon (PKCepsilon) and that these genes are involved in the cardioprotective mechanism of action of urocortin.	Urocortins	251-260	potassium inwardly rectifying channel subfamily J member 8	Homo sapiens	62-68
15358201-2	2004	An ATP sensitive inwardly rectifying potassium channel, Katp (Kir6.1), the enzyme calcium independent phospholipase A2 (iPLA2), and protein kinase C epsilon (PKCepsilon) and that these genes are involved in the cardioprotective mechanism of action of urocortin.	Urocortins	251-260	patatin like phospholipase domain containing 2	Homo sapiens	82-118
15358201-2	2004	An ATP sensitive inwardly rectifying potassium channel, Katp (Kir6.1), the enzyme calcium independent phospholipase A2 (iPLA2), and protein kinase C epsilon (PKCepsilon) and that these genes are involved in the cardioprotective mechanism of action of urocortin.	Urocortins	251-260	phospholipase A2 group VI	Homo sapiens	120-125
15358201-2	2004	An ATP sensitive inwardly rectifying potassium channel, Katp (Kir6.1), the enzyme calcium independent phospholipase A2 (iPLA2), and protein kinase C epsilon (PKCepsilon) and that these genes are involved in the cardioprotective mechanism of action of urocortin.	Urocortins	251-260	protein kinase C epsilon	Homo sapiens	132-156
15358201-2	2004	An ATP sensitive inwardly rectifying potassium channel, Katp (Kir6.1), the enzyme calcium independent phospholipase A2 (iPLA2), and protein kinase C epsilon (PKCepsilon) and that these genes are involved in the cardioprotective mechanism of action of urocortin.	Urocortins	251-260	protein kinase C epsilon	Homo sapiens	158-168
15358201-4	2004	Using pharmacological agents to Katp channels and iPLA2 and synthetic peptide inhibitors of PKCepsilon, we go on to demonstrate that these three gene products are involved in the urocortin induced protection of cardiac myocyte mitochondria.	Urocortins	179-188	phospholipase A2 group VI	Homo sapiens	50-55
15358201-4	2004	Using pharmacological agents to Katp channels and iPLA2 and synthetic peptide inhibitors of PKCepsilon, we go on to demonstrate that these three gene products are involved in the urocortin induced protection of cardiac myocyte mitochondria.	Urocortins	179-188	protein kinase C epsilon	Homo sapiens	92-102
15206947-4	2004	Soluble isoforms could modulate cell response with CRFR1e attenuating and CRFR1h amplifying CRFR1alpha-coupled cAMP production stimulated by urocortin.	Urocortins	141-150	corticotropin releasing hormone receptor 1	Homo sapiens	74-79
15228601-8	2004	Both TNFalpha and leptin independently facilitated receptor-mediated transport of urocortin across the BBB.	Urocortins	82-91	tumor necrosis factor	Mus musculus	5-13
15066020-3	2004	Peripheral injection of CRF or urocortin inhibits gastric emptying and motility through interaction with CRF2 receptors and stimulates colonic transit, motility, Fos expression in myenteric neurones and defecation through activation of CRF1 receptors.	Urocortins	31-40	corticotropin releasing hormone receptor 2	Rattus norvegicus	105-109
15093697-1	2004	Stresscopin (SCP or urocortin III), a member of the corticotropin-releasing factor (CRF) neuropeptide family, is a high-affinity ligand for the type 2 CRF receptor (CRF(2)).	Urocortins	20-33	cysteine-rich secretory protein 3	Rattus norvegicus	13-16
15093697-1	2004	Stresscopin (SCP or urocortin III), a member of the corticotropin-releasing factor (CRF) neuropeptide family, is a high-affinity ligand for the type 2 CRF receptor (CRF(2)).	Urocortins	20-33	corticotropin releasing hormone	Rattus norvegicus	52-82
15066020-3	2004	Peripheral injection of CRF or urocortin inhibits gastric emptying and motility through interaction with CRF2 receptors and stimulates colonic transit, motility, Fos expression in myenteric neurones and defecation through activation of CRF1 receptors.	Urocortins	31-40	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	162-165
15066020-3	2004	Peripheral injection of CRF or urocortin inhibits gastric emptying and motility through interaction with CRF2 receptors and stimulates colonic transit, motility, Fos expression in myenteric neurones and defecation through activation of CRF1 receptors.	Urocortins	31-40	corticotropin releasing hormone receptor 1	Rattus norvegicus	236-240
14657255-1	2004	Activation of CRH receptors type 1 (CRH-R1) by CRH or urocortin (UCN) leads to stimulation of multiple G proteins with consequent effects on diverse signaling cascades in a tissue-specific manner.	Urocortins	54-63	corticotropin releasing hormone receptor 1	Homo sapiens	14-34
15000874-2	2004	Urocortin shows a significantly high sequence homology to CRF, and the concurrent expression of type-2 CRF (CRF2) receptors with urocortin in the heart suggests that urocortin may play a physiological role in the cardiac function.	Urocortins	129-138	corticotropin releasing hormone receptor 2	Homo sapiens	108-112
14657255-1	2004	Activation of CRH receptors type 1 (CRH-R1) by CRH or urocortin (UCN) leads to stimulation of multiple G proteins with consequent effects on diverse signaling cascades in a tissue-specific manner.	Urocortins	54-63	corticotropin releasing hormone receptor 1	Homo sapiens	36-42
14657255-1	2004	Activation of CRH receptors type 1 (CRH-R1) by CRH or urocortin (UCN) leads to stimulation of multiple G proteins with consequent effects on diverse signaling cascades in a tissue-specific manner.	Urocortins	54-63	corticotropin releasing hormone	Homo sapiens	14-17
14657255-1	2004	Activation of CRH receptors type 1 (CRH-R1) by CRH or urocortin (UCN) leads to stimulation of multiple G proteins with consequent effects on diverse signaling cascades in a tissue-specific manner.	Urocortins	54-63	urocortin	Homo sapiens	65-68
15004403-4	2004	Urocortins, e.g. urocortin 1 and urocortin 3 (stresscopin), are endogenous ligands for the corticotropin-releasing factor (CRF) receptors, particularly CRF type 2 receptor, that mediates a vasodilator action, a positive inotropic action and a central appetite-inhibiting action.	Urocortins	0-10	urocortin 3	Homo sapiens	33-44
15004403-4	2004	Urocortins, e.g. urocortin 1 and urocortin 3 (stresscopin), are endogenous ligands for the corticotropin-releasing factor (CRF) receptors, particularly CRF type 2 receptor, that mediates a vasodilator action, a positive inotropic action and a central appetite-inhibiting action.	Urocortins	0-10	corticotropin releasing hormone	Homo sapiens	91-121
15004403-4	2004	Urocortins, e.g. urocortin 1 and urocortin 3 (stresscopin), are endogenous ligands for the corticotropin-releasing factor (CRF) receptors, particularly CRF type 2 receptor, that mediates a vasodilator action, a positive inotropic action and a central appetite-inhibiting action.	Urocortins	17-28	corticotropin releasing hormone	Homo sapiens	91-121
14576187-3	2004	We previously showed that restraint stress, as well as CRH and its structurally related urocortin (Ucn), could activate mast cells and trigger mast cell-dependent vascular permeability.	Urocortins	88-97	corticotropin releasing hormone	Homo sapiens	55-58
14576187-3	2004	We previously showed that restraint stress, as well as CRH and its structurally related urocortin (Ucn), could activate mast cells and trigger mast cell-dependent vascular permeability.	Urocortins	88-97	urocortin	Homo sapiens	99-102
14563694-0	2003	Urocortin protects cardiac myocytes from ischemia/reperfusion injury by attenuating calcium-insensitive phospholipase A2 gene expression.	Urocortins	0-9	phospholipase A2 group IB	Rattus norvegicus	104-120
14563694-3	2003	Levels of lysophosphatidylcholine, a toxic metabolite of phospholipase A2, were lowered by 30% in myocytes treated with urocortin for 24 h and by 50% with the irreversible iPLA2 inhibitor bromoenol lactone compared with controls.	Urocortins	120-129	phospholipase A2 group IB	Rattus norvegicus	57-73
14563694-3	2003	Levels of lysophosphatidylcholine, a toxic metabolite of phospholipase A2, were lowered by 30% in myocytes treated with urocortin for 24 h and by 50% with the irreversible iPLA2 inhibitor bromoenol lactone compared with controls.	Urocortins	120-129	phospholipase A2 group VI	Rattus norvegicus	172-177
12841938-5	2003	In the arterial segments precontracted with endothelin-1, urocortin produced concentration-dependent relaxation, and the order of sensitivity was: tail > basilar > coronary.	Urocortins	58-67	endothelin 1	Rattus norvegicus	44-56
12972328-7	2003	We speculate that stress or lack of CRH may increase urocortin, which in turn down-regulates CRH-R2 mRNA expression in the heart.	Urocortins	53-62	corticotropin releasing hormone	Mus musculus	36-39
12972328-7	2003	We speculate that stress or lack of CRH may increase urocortin, which in turn down-regulates CRH-R2 mRNA expression in the heart.	Urocortins	53-62	corticotropin releasing hormone receptor 2	Mus musculus	93-99
12742625-12	2003	Urocortin induced a similar pattern of Fos response in the brain and the spinal cord.	Urocortins	0-9	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	39-42
14517183-3	2003	In renal artery segments precontracted with endothelin-1 (1 nm), urocortin (1 pm-10 nm) produced concentration-dependent relaxation, which was similar in the arteries from male and female rats.	Urocortins	65-74	endothelin 1	Rattus norvegicus	44-56
14508243-0	2003	Vasodilative effects of urocortin II via protein kinase A and a mitogen-activated protein kinase in rat thoracic aorta.	Urocortins	24-36	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	41-57
14508243-3	2003	In the present study, the authors examined the hypothesis that urocortin II or urocortin III, in addition to urocortin, produces vasodilation as a candidate for natural ligands of CRF R2beta in rat thoracic aorta.	Urocortins	79-92	corticotropin releasing hormone receptor 2	Rattus norvegicus	180-186
14508243-3	2003	In the present study, the authors examined the hypothesis that urocortin II or urocortin III, in addition to urocortin, produces vasodilation as a candidate for natural ligands of CRF R2beta in rat thoracic aorta.	Urocortins	63-72	corticotropin releasing hormone receptor 2	Rattus norvegicus	180-186
14508243-8	2003	SB203580, a p38 mitogen-activated protein (MAP) kinase inhibitor, also inhibited the effects of urocortin and urocortin II on vasodilation.	Urocortins	96-105	mitogen activated protein kinase 14	Rattus norvegicus	12-15
12746287-2	2003	In addition to hypothalamus, CRH and its analog urocortin (Ucn) are also secreted locally outside the brain where they activate mast cells leading to inflammation; however, the level of CRH and Ucn or mast cell mediators has not been examined in products of conception (POC).	Urocortins	48-57	corticotropin releasing hormone	Homo sapiens	29-32
12746287-2	2003	In addition to hypothalamus, CRH and its analog urocortin (Ucn) are also secreted locally outside the brain where they activate mast cells leading to inflammation; however, the level of CRH and Ucn or mast cell mediators has not been examined in products of conception (POC).	Urocortins	48-57	urocortin	Homo sapiens	59-62
12746287-2	2003	In addition to hypothalamus, CRH and its analog urocortin (Ucn) are also secreted locally outside the brain where they activate mast cells leading to inflammation; however, the level of CRH and Ucn or mast cell mediators has not been examined in products of conception (POC).	Urocortins	48-57	corticotropin releasing hormone	Homo sapiens	186-189
12660427-2	2003	Corticotropin-releasing hormone (CRH) and its structural analogue urocortin (Ucn) were shown to trigger skin mast cell activation and vascular permeability.	Urocortins	66-75	corticotropin releasing hormone	Rattus norvegicus	0-31
12663088-6	2003	Western blot analysis of cultured BMEC identified CRF receptor protein; stimulation with CRF, or it structural analogue urocortin (Ucn) showed that the receptor is functionally coupled to adenylate cyclase as it increased cyclic AMP (cAMP) levels by 2-fold.	Urocortins	120-129	urocortin	Rattus norvegicus	131-134
12618244-6	2003	RESULTS: In 9,11-dideoxy-11alpha,9alpha-epoxy-methanoprostaglandin F(2alpha) (U46619)-contracted rings, urocortin-induced relaxation (pD(2): 8.40+/-0.04) was significantly reduced by cyclic AMP-dependent protein kinase (PKA) inhibitors, Rp-cAMPS triethylamine (Rp-cAMPS) and KT 5720.	Urocortins	104-113	calmodulin 2, pseudogene 1	Rattus norvegicus	240-245
12618244-6	2003	RESULTS: In 9,11-dideoxy-11alpha,9alpha-epoxy-methanoprostaglandin F(2alpha) (U46619)-contracted rings, urocortin-induced relaxation (pD(2): 8.40+/-0.04) was significantly reduced by cyclic AMP-dependent protein kinase (PKA) inhibitors, Rp-cAMPS triethylamine (Rp-cAMPS) and KT 5720.	Urocortins	104-113	calmodulin 2, pseudogene 1	Rattus norvegicus	264-269
12618244-10	2003	Treatment with TEA(+) or Rp-cAMPS inhibited the relaxant effect of urocortin in 35 mmol/l K(+)-contracted rings.	Urocortins	67-76	calmodulin 2, pseudogene 1	Rattus norvegicus	28-33
12660427-2	2003	Corticotropin-releasing hormone (CRH) and its structural analogue urocortin (Ucn) were shown to trigger skin mast cell activation and vascular permeability.	Urocortins	66-75	corticotropin releasing hormone	Rattus norvegicus	33-36
12660427-2	2003	Corticotropin-releasing hormone (CRH) and its structural analogue urocortin (Ucn) were shown to trigger skin mast cell activation and vascular permeability.	Urocortins	77-80	corticotropin releasing hormone	Rattus norvegicus	0-31
12660427-2	2003	Corticotropin-releasing hormone (CRH) and its structural analogue urocortin (Ucn) were shown to trigger skin mast cell activation and vascular permeability.	Urocortins	77-80	corticotropin releasing hormone	Rattus norvegicus	33-36
12535698-3	2002	Combined peripheral administration of leptin and urocortin (UCN) significantly decreased food intake, whereas neither one showed an effect when given alone in the same doses.	Urocortins	49-58	urocortin	Homo sapiens	60-63
12388260-1	2003	The major objective of this study was to determine whether urocortin, a member of the corticotrophin-releasing factor (CRF) family, protects adult rat cardiomyocytes from ischemia that has been simulated by glucose deprivation and acidosis.	Urocortins	59-68	corticotropin releasing hormone	Rattus norvegicus	86-117
14555790-0	2003	The cardioprotective agent urocortin induces expression of CT-1.	Urocortins	27-36	cardiotrophin 1	Homo sapiens	59-63
12492439-8	2002	Both CRH and urocortin caused a dose-dependent rise in hippocampal serotonin (maximally 350% of baseline) and 5-hydroxyindoleacetic acid levels, suggesting the involvement of CRH receptor type 1.	Urocortins	13-22	corticotropin releasing hormone	Rattus norvegicus	175-178
12492439-9	2002	Because the effects of urocortin were prolonged, CRH receptor type 2 could play a role in a later phase of the neurotransmitter response.	Urocortins	23-32	corticotropin releasing hormone	Rattus norvegicus	49-52
12373783-2	2002	Urocortin (Ucn), a 40-amino-acid neuropeptide recently isolated from the rat brain, is the newest member of this family.	Urocortins	0-9	urocortin	Rattus norvegicus	11-14
11879793-1	2002	The corticotropin-releasing hormone (CRH) system, including CRH and urocortin (UCN), is implicated in the central control of appetite and energy metabolism.	Urocortins	68-77	corticotropin releasing hormone	Rattus norvegicus	4-35
12413940-0	2002	GRK3 regulation during CRF- and urocortin-induced CRF1 receptor desensitization.	Urocortins	32-41	G protein-coupled receptor kinase 3	Homo sapiens	0-4
12413940-5	2002	Neither GRK3 nor GRK2 expression increased in Y79 cells exposed to urocortin for 10 min to 48 h. We hypothesize that GRK3 upregulation may be a cellular negative feedback process directed at maximizing CRF(1) receptor desensitization by heightening GRK3 phosphorylating capacity during prolonged exposure to high CRF.	Urocortins	67-76	G protein-coupled receptor kinase 3	Homo sapiens	117-121
12413940-5	2002	Neither GRK3 nor GRK2 expression increased in Y79 cells exposed to urocortin for 10 min to 48 h. We hypothesize that GRK3 upregulation may be a cellular negative feedback process directed at maximizing CRF(1) receptor desensitization by heightening GRK3 phosphorylating capacity during prolonged exposure to high CRF.	Urocortins	67-76	G protein-coupled receptor kinase 3	Homo sapiens	117-121
12392842-1	2002	OBJECTIVES: The goal of this study was to determine the bioactivity of urocortin (Ucn) in experimental heart failure (HF).	Urocortins	71-80	urocortin	Ovis aries	82-85
12234964-3	2002	We report that urocortin specifically induces enhanced expression of the Kir 6.1 cardiac potassium channel subunit.	Urocortins	15-24	potassium inwardly rectifying channel subfamily J member 8	Homo sapiens	73-80
12234964-4	2002	On the basis of this finding, we showed that the cardioprotective effect of urocortin both in isolated cardiac cells and in the intact heart is specifically blocked by both generalized and mitochondrial-specific K(ATP) channel blockers, whereas the cardioprotective effect of cardiotrophin-1 is unaffected.	Urocortins	76-85	cardiotrophin 1	Homo sapiens	276-291
12201805-10	2002	CRH/urocortin, via specific receptor isoforms, is now able to activate Gq and potentially enhance the oxytocin-driven generation of inositol triphosphate.	Urocortins	4-13	corticotropin releasing hormone	Homo sapiens	0-3
12201805-11	2002	In addition, CRH/urocortin, via specific CRH receptor subtypes, may generate prostaglandins from the fetal membranes and decidua, play a role in placental vasodilatation and participate in fetal adrenal function and organ maturation.	Urocortins	17-26	corticotropin releasing hormone	Homo sapiens	13-16
12201805-11	2002	In addition, CRH/urocortin, via specific CRH receptor subtypes, may generate prostaglandins from the fetal membranes and decidua, play a role in placental vasodilatation and participate in fetal adrenal function and organ maturation.	Urocortins	17-26	corticotropin releasing hormone	Homo sapiens	41-44
12113883-4	2002	Acting on the same CRF receptors, urocortin stimulates myometrial contractility and ACTH and prostaglandin release from cultured human placental cells.	Urocortins	34-43	proopiomelanocortin	Homo sapiens	84-88
12010772-3	2002	We investigated CRF receptor-mediated actions of rat urocortin (rUcn) injected intracisternally (ic) on gastric motor function.	Urocortins	53-62	urocortin	Rattus norvegicus	64-68
12027405-2	2002	CT-1 and the corticotrophin releasing hormone-like hormone urocortin protect cardiac myocytes by the same p42/44 mitogen activated protein kinase (p42/44 MAPK) dependent pathway.	Urocortins	59-68	cardiotrophin 1	Rattus norvegicus	0-50
12027405-2	2002	CT-1 and the corticotrophin releasing hormone-like hormone urocortin protect cardiac myocytes by the same p42/44 mitogen activated protein kinase (p42/44 MAPK) dependent pathway.	Urocortins	59-68	mitogen activated protein kinase 1	Rattus norvegicus	147-158
12027405-9	2002	These results identify urocortin as a novel hypertrophic and protective agent whose hypertrophic effect is mediated by a distinct pathway to that activated by CT-1, although the two factors mediate protection via the same pathway.	Urocortins	23-32	cardiotrophin 1	Rattus norvegicus	159-163
11976272-1	2002	Urocortin, an endogenous peptide structurally related to corticotropin-releasing factor (CRF), has potent cardiovascular effects, suggesting that it may be of significance in cardiovascular regulation.	Urocortins	0-9	corticotropin releasing hormone	Homo sapiens	57-87
11976272-4	2002	In the segments at basal resting tone, urocortin did not produce any effect, but in the segments precontracted with endothelin-1 (1 - 10 nM), urocortin (1 pM - 10 nM) produced concentration-dependent relaxation.	Urocortins	142-151	endothelin 1	Homo sapiens	116-128
11991736-0	2002	Activation of protein kinase B/Akt by urocortin is essential for its ability to protect cardiac cells against hypoxia/reoxygenation-induced cell death.	Urocortins	38-47	AKT serine/threonine kinase 1	Rattus norvegicus	31-34
11879793-1	2002	The corticotropin-releasing hormone (CRH) system, including CRH and urocortin (UCN), is implicated in the central control of appetite and energy metabolism.	Urocortins	68-77	corticotropin releasing hormone	Rattus norvegicus	37-40
11879793-1	2002	The corticotropin-releasing hormone (CRH) system, including CRH and urocortin (UCN), is implicated in the central control of appetite and energy metabolism.	Urocortins	68-77	urocortin	Rattus norvegicus	79-82
11834446-4	2002	In this study we show, for the first time, that urocortin induces the expression of hsp90 but not hsp70 in primary cultures of rat neonatal cardiac myocytes.	Urocortins	48-57	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	84-89
11792665-1	2002	The hypothalamic paraventricular nucleus (PVN) plays a primary role in energy homeostasis, and urocortin (UCN) decreases feeding after injection into the PVN.	Urocortins	95-104	urocortin	Rattus norvegicus	106-109
11834446-5	2002	Levels of hsp90 protein increase by 1.5-fold over untreated cells within 10 min of urocortin treatment and are sustained for 24 h with a maximal increase of 2.5-fold at 60 min (P<0.05 at all time points).	Urocortins	83-92	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	10-15
11834446-6	2002	The increase in hsp90 expression by urocortin was not inhibited by actinomycin D, and urocortin failed to increase hsp90 promoter activity.	Urocortins	36-45	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	16-21
11834446-7	2002	Urocortin induction of hsp90 was inhibited by the MEK1/2 inhibitor PD98059 (P<0.001) and by cycloheximide, and both inhibitors abrogate urocortin-mediated cardioprotection (P<0.05 for cycloheximide, P<0.001 for PD98059).	Urocortins	139-148	urocortin	Rattus norvegicus	0-9
11834446-7	2002	Urocortin induction of hsp90 was inhibited by the MEK1/2 inhibitor PD98059 (P<0.001) and by cycloheximide, and both inhibitors abrogate urocortin-mediated cardioprotection (P<0.05 for cycloheximide, P<0.001 for PD98059).	Urocortins	139-148	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	23-28
11834446-8	2002	Hence, MEK1/2 and protein synthesis are involved in the cardioprotective effect of urocortin against hypoxic-mediated cell death, possibly due to an increase in expression of hsp90 protein.	Urocortins	83-92	mitogen activated protein kinase kinase 1	Rattus norvegicus	7-13
11834446-8	2002	Hence, MEK1/2 and protein synthesis are involved in the cardioprotective effect of urocortin against hypoxic-mediated cell death, possibly due to an increase in expression of hsp90 protein.	Urocortins	83-92	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	175-180
11834446-9	2002	This is the first report of heat shock protein induction by urocortin or any other member of the corticotrophin-releasing hormone family.	Urocortins	60-69	selenoprotein K	Rattus norvegicus	28-46
11425856-6	2001	Following thrombin cleavage, the purified protein (bNT-CRFR1) binds astressin and the agonist urocortin with high affinity.	Urocortins	94-103	coagulation factor II, thrombin	Homo sapiens	10-18
11784785-7	2002	Using subtype-selective CRH receptor antagonists, we provide evidence that the neuroprotective effect of exogenously added urocortin is mediated by CRHR1.	Urocortins	123-132	corticotropin releasing hormone	Homo sapiens	24-27
11784785-7	2002	Using subtype-selective CRH receptor antagonists, we provide evidence that the neuroprotective effect of exogenously added urocortin is mediated by CRHR1.	Urocortins	123-132	corticotropin releasing hormone receptor 1	Homo sapiens	148-153
11739017-5	2001	infusion of urocortin on feed intake and endocrine profiles of LH, GH, IGF-I, cortisol and leptin in ovariectomized ewes.	Urocortins	12-21	insulin-like growth factor 1	Rattus norvegicus	71-76
11682149-1	2001	The effect of intracisternal injection of urocortin, an endogenous ligand for corticotropin-releasing factor (CRF) 2 receptor, on carbon tetrachloride (CCl4)-induced acute liver injury was investigated in rats.	Urocortins	42-51	C-C motif chemokine ligand 4	Rattus norvegicus	152-156
11682149-2	2001	Intracisternal injection of urocortin dose-dependently enhanced elevation of serum alanine aminotransferase and aspartate aminotransferase levels induced by CCl4.	Urocortins	28-37	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	112-138
11682149-2	2001	Intracisternal injection of urocortin dose-dependently enhanced elevation of serum alanine aminotransferase and aspartate aminotransferase levels induced by CCl4.	Urocortins	28-37	C-C motif chemokine ligand 4	Rattus norvegicus	157-161
11682149-3	2001	Intracisternal urocortin also aggravated CCl4-induced histological changes of the liver.	Urocortins	15-24	C-C motif chemokine ligand 4	Rattus norvegicus	41-45
11682149-4	2001	The aggravating effect of central urocortin on CCl4-induced acute liver injury was abolished by chemical sympathectomy, but not by vagotomy.	Urocortins	34-43	C-C motif chemokine ligand 4	Rattus norvegicus	47-51
11641109-5	2001	The CRF-R1/CRF-R2 antagonist astressin B (30 microg/kg ip) and the selective CRF-R2 antagonist antisauvagine-30 (100 microg/kg ip) completely antagonized urocortin action, whereas the selective CRF-R1 antagonist CP-154,526 (10 mg/kg ip) had no effect.	Urocortins	154-163	corticotropin releasing hormone receptor 1	Mus musculus	4-10
11641109-5	2001	The CRF-R1/CRF-R2 antagonist astressin B (30 microg/kg ip) and the selective CRF-R2 antagonist antisauvagine-30 (100 microg/kg ip) completely antagonized urocortin action, whereas the selective CRF-R1 antagonist CP-154,526 (10 mg/kg ip) had no effect.	Urocortins	154-163	corticotropin releasing hormone receptor 2	Mus musculus	77-83
11641109-10	2001	These data indicate that intraperitoneal urocortin-induced decrease in feeding is only partly mediated by CRF-R2, whereas urocortin action to delay gastric emptying of a meal involves primarily CRF-R2.	Urocortins	41-50	corticotropin releasing hormone receptor 2	Mus musculus	106-112
11549672-8	2001	These findings suggest that, like CRH, urocortin is present in peripheral inflammatory sites, such as rheumatoid synovium, and acts as an immune-inflammatory mediator.	Urocortins	39-48	corticotropin releasing hormone	Homo sapiens	34-37
11597609-3	2001	The recently identified CRH-related peptide, urocortin (UCN), also binds with high affinity to CRH receptor subtypes and decreases food intake in food-deprived and non-deprived rats.	Urocortins	45-54	corticotropin releasing hormone	Rattus norvegicus	24-27
11597609-3	2001	The recently identified CRH-related peptide, urocortin (UCN), also binds with high affinity to CRH receptor subtypes and decreases food intake in food-deprived and non-deprived rats.	Urocortins	45-54	urocortin	Rattus norvegicus	56-59
11597609-3	2001	The recently identified CRH-related peptide, urocortin (UCN), also binds with high affinity to CRH receptor subtypes and decreases food intake in food-deprived and non-deprived rats.	Urocortins	45-54	corticotropin releasing hormone	Rattus norvegicus	95-98
11425856-6	2001	Following thrombin cleavage, the purified protein (bNT-CRFR1) binds astressin and the agonist urocortin with high affinity.	Urocortins	94-103	corticotropin releasing hormone receptor 1	Homo sapiens	55-60
11459800-9	2001	Interestingly, treatment with urocortin significantly decreases CRH receptor type 2 mRNA in cultured cardiomyocytes.	Urocortins	30-39	corticotropin releasing hormone	Mus musculus	64-67
11337084-3	2001	Comparative pharmacology of CRH receptor agonists suggests that CRH, urocortin, sauvagine and urotensin consistently mimic, and CRH receptor antagonists consistently lessen, functional consequences of stressor exposure.	Urocortins	69-78	corticotropin releasing hormone	Mus musculus	28-31
11250659-3	2001	In addition, urocortin (Ucn), a new member of the CRF family, has been reported to have much greater affinity for CRF-R2 than CRF.	Urocortins	13-22	corticotropin releasing hormone receptor 2	Rattus norvegicus	114-120
11250659-3	2001	In addition, urocortin (Ucn), a new member of the CRF family, has been reported to have much greater affinity for CRF-R2 than CRF.	Urocortins	24-27	corticotropin releasing hormone receptor 2	Rattus norvegicus	114-120
11179597-4	2001	Rat CRFBP was pharmacologically characterized employing a competition binding assay with tritium-labeled rat urocortin.	Urocortins	109-118	corticotropin releasing hormone binding protein	Rattus norvegicus	4-9
11337087-3	2001	Both CRH and urocortin mediate their endocrine and/or synaptic effects via two classes of CRH receptors.	Urocortins	13-22	corticotropin releasing hormone	Mus musculus	90-93
11337087-4	2001	Similarly, both CRH and urocortin bind to the CRH-binding protein (CRH-BP).	Urocortins	24-33	corticotropin releasing hormone binding protein	Mus musculus	46-65
11337087-4	2001	Similarly, both CRH and urocortin bind to the CRH-binding protein (CRH-BP).	Urocortins	24-33	corticotropin releasing hormone binding protein	Mus musculus	67-73
11337087-5	2001	This secreted binding protein is smaller than the CRH receptors, but binds CRH and urocortin with an affinity equal to or greater than that of the receptors, and blocks CRH-mediated ACTH release in vitro.	Urocortins	83-92	corticotropin releasing hormone	Mus musculus	50-53
11337087-6	2001	Several regions of CRH-BP expression colocalize with sites of CRH synthesis or release, suggesting that this binding protein may have a profound impact on the biological activity of CRH (or urocortin).	Urocortins	190-199	corticotropin releasing hormone binding protein	Mus musculus	19-25
11337087-6	2001	Several regions of CRH-BP expression colocalize with sites of CRH synthesis or release, suggesting that this binding protein may have a profound impact on the biological activity of CRH (or urocortin).	Urocortins	190-199	corticotropin releasing hormone	Mus musculus	19-22
11337087-6	2001	Several regions of CRH-BP expression colocalize with sites of CRH synthesis or release, suggesting that this binding protein may have a profound impact on the biological activity of CRH (or urocortin).	Urocortins	190-199	corticotropin releasing hormone	Mus musculus	62-65
11337096-3	2001	The diversity of actions of urocortin on behaviour, appetite, inflammation and the cardiovascular system suggest that this peptide may be an endogenous factor mediating actions previously attributed to CRH.	Urocortins	28-37	corticotropin releasing hormone	Homo sapiens	202-205
11264720-6	2001	In the SON, urocortin was localized to vasopressin and oxytocin neurones but was rarely seen in CRF-positive cells.	Urocortins	12-21	arginine vasopressin	Rattus norvegicus	39-50
11403094-3	2001	VMH CRH-R2 is more important than CRH-R1 in mediating anorexic effect of CRH or urocortin (UCN) and stress-induced reduction of food intake.	Urocortins	80-89	corticotropin releasing hormone receptor 2	Mus musculus	4-10
11403094-3	2001	VMH CRH-R2 is more important than CRH-R1 in mediating anorexic effect of CRH or urocortin (UCN) and stress-induced reduction of food intake.	Urocortins	80-89	corticotropin releasing hormone	Mus musculus	4-7
11403094-3	2001	VMH CRH-R2 is more important than CRH-R1 in mediating anorexic effect of CRH or urocortin (UCN) and stress-induced reduction of food intake.	Urocortins	91-94	corticotropin releasing hormone receptor 2	Mus musculus	4-10
11403094-3	2001	VMH CRH-R2 is more important than CRH-R1 in mediating anorexic effect of CRH or urocortin (UCN) and stress-induced reduction of food intake.	Urocortins	91-94	corticotropin releasing hormone	Mus musculus	4-7
11403094-6	2001	CRH-R1 mediates CRH-induced blood pressure elevation, while peripheral CRH-R2 mediates the hypotensive effect of systemically administered UCN and CRH.	Urocortins	139-142	corticotropin releasing hormone receptor 2	Mus musculus	71-77
11403094-8	2001	Peripheral CRH-R2 mediates UCN-induced mast cell degranulation, vascular permeability, and abdominal surgery-induced gastric stasis.	Urocortins	27-30	corticotropin releasing hormone receptor 2	Mus musculus	11-17
12045360-1	2001	OBJECTIVE: Corticotropin-releasing factor receptor type 2 (CRF R2) messenger RNA (mRNA) expression in the rodent heart or vessels is modulated by exposure to urocortin and glucocorticoids.	Urocortins	158-167	corticotropin releasing hormone receptor 2	Rattus norvegicus	11-57
12045360-1	2001	OBJECTIVE: Corticotropin-releasing factor receptor type 2 (CRF R2) messenger RNA (mRNA) expression in the rodent heart or vessels is modulated by exposure to urocortin and glucocorticoids.	Urocortins	158-167	corticotropin releasing hormone receptor 2	Rattus norvegicus	59-65
11113078-9	2000	CONCLUSIONS: These results demonstrate that CRF acts peripherally to stimulate colonic motility and that CRF-R1 is primarily involved in mediating IP CRF/urocortin- and water avoidance stress-induced colonic motor response.	Urocortins	154-163	corticotropin releasing hormone receptor 1	Rattus norvegicus	105-111
10919255-0	2000	Modulation of urocortin-induced hypophagia and weight loss by corticotropin-releasing factor receptor 1 deficiency in mice.	Urocortins	14-23	corticotropin releasing hormone receptor 1	Mus musculus	62-103
11117536-0	2000	Urocortin, but not corticotropin-releasing hormone (CRH), activates the mitogen-activated protein kinase signal transduction pathway in human pregnant myometrium: an effect mediated via R1alpha and R2beta CRH receptor subtypes and stimulation of Gq-proteins.	Urocortins	0-9	corticotropin releasing hormone	Homo sapiens	205-208
11117536-1	2000	CRH and CRH-related peptides such as urocortin mediate their actions in the human myometrium via activation of two distinct classes of CRH receptors, R1 and R2.	Urocortins	37-46	corticotropin releasing hormone	Homo sapiens	0-3
11117536-1	2000	CRH and CRH-related peptides such as urocortin mediate their actions in the human myometrium via activation of two distinct classes of CRH receptors, R1 and R2.	Urocortins	37-46	corticotropin releasing hormone	Homo sapiens	8-11
11117536-1	2000	CRH and CRH-related peptides such as urocortin mediate their actions in the human myometrium via activation of two distinct classes of CRH receptors, R1 and R2.	Urocortins	37-46	corticotropin releasing hormone	Homo sapiens	8-11
11117536-8	2000	Studies on Gq protein activation using [alpha-32P]-GTP-gamma-azidoanilide and IP3 production in cells expressing the R1alpha or R2beta CRH receptors demonstrated that urocortin was 10 times more potent than CRH.	Urocortins	167-176	corticotropin releasing hormone	Homo sapiens	135-138
11117536-9	2000	Moreover, urocortin (UCN) generated peak responses that were 50-70% greater than CRH in activating the Gq protein and stimulating IP3 production.	Urocortins	10-19	urocortin	Homo sapiens	21-24
11095927-1	2000	Urocortin, a recently identified peptide of the corticotropin releasing hormone (CRH) peptide family, has potent vasodilatory effects in the human fetal placental circulation in vitro, promoting us to hypothesize that urocortin is produced locally to regulate uteroplacental vascular tone during pregnancy.	Urocortins	218-227	corticotropin releasing hormone	Homo sapiens	48-79
11095927-1	2000	Urocortin, a recently identified peptide of the corticotropin releasing hormone (CRH) peptide family, has potent vasodilatory effects in the human fetal placental circulation in vitro, promoting us to hypothesize that urocortin is produced locally to regulate uteroplacental vascular tone during pregnancy.	Urocortins	218-227	corticotropin releasing hormone	Homo sapiens	81-84
11026651-3	2000	Therefore, we examined the effect of glucocorticoid treatment, adrenalectomy, and systemic administration of urocortin, a possible endogenous ligand for CRHR-2, on heart CRHR-2 mRNA levels in male Wistar rats, using in situ hybridization histochemistry.	Urocortins	109-118	corticotropin releasing hormone receptor 2	Rattus norvegicus	153-159
11026651-3	2000	Therefore, we examined the effect of glucocorticoid treatment, adrenalectomy, and systemic administration of urocortin, a possible endogenous ligand for CRHR-2, on heart CRHR-2 mRNA levels in male Wistar rats, using in situ hybridization histochemistry.	Urocortins	109-118	corticotropin releasing hormone receptor 2	Rattus norvegicus	170-176
11026651-4	2000	CRHR-2 mRNA in the heart was significantly decreased 9 h after systemic administration of urocortin (5 microg/kg b.w.).	Urocortins	90-99	corticotropin releasing hormone receptor 2	Rattus norvegicus	0-6
10986336-0	2000	Astressin, a corticotropin releasing factor antagonist, reverses the anxiogenic effects of urocortin when administered into the basolateral amygdala.	Urocortins	91-100	corticotropin releasing hormone	Rattus norvegicus	13-43
10986336-1	2000	Previous work in our laboratory has shown that Urocortin (Ucn), a peptide related to corticotropin releasing factor (CRF), injected into the basolateral nucleus of the amygdala (BLA) in male Wistar rats would result in an anxiogenic response as measured in the social interaction (SI) test.	Urocortins	47-56	urocortin	Rattus norvegicus	58-61
10986336-1	2000	Previous work in our laboratory has shown that Urocortin (Ucn), a peptide related to corticotropin releasing factor (CRF), injected into the basolateral nucleus of the amygdala (BLA) in male Wistar rats would result in an anxiogenic response as measured in the social interaction (SI) test.	Urocortins	47-56	corticotropin releasing hormone	Rattus norvegicus	85-115
12045360-10	2001	CONCLUSION: The multifactorial regulation of CRF R2beta mRNA expression in the A7r5 cells serves to limit the inotropic and chronotropic effects of CRF R2 agonists such as urocortin during prolonged physical or immune challenge.	Urocortins	172-181	corticotropin releasing hormone receptor 2	Rattus norvegicus	45-51
11118786-0	2000	Feed intake and serum GH, LH and cortisol in gilts after intracerebroventricular or intravenous injection of urocortin.	Urocortins	109-118	FEEDIN	Sus scrofa	0-11
11118786-10	2000	These data provide evidence that urocortin modulates GH and LH concentrations and suppresses feed intake in gilts via mechanisms which may be independent of cortisol and may depend upon dose and route of administration.	Urocortins	33-42	FEEDIN	Sus scrofa	93-104
10919255-1	2000	Intracerebroventricular injection of CRF or urocortin (Ucn) reduces appetite and body weight.	Urocortins	44-53	urocortin	Mus musculus	55-58
10690896-1	2000	Since the skin produces POMC peptides, in the present work we investigated local production of urocortin, a peptide related to CRH, the normal endogenous stimulant for POMC.	Urocortins	95-104	corticotropin releasing hormone	Homo sapiens	127-130
11095927-1	2000	Urocortin, a recently identified peptide of the corticotropin releasing hormone (CRH) peptide family, has potent vasodilatory effects in the human fetal placental circulation in vitro, promoting us to hypothesize that urocortin is produced locally to regulate uteroplacental vascular tone during pregnancy.	Urocortins	218-227	urocortin	Homo sapiens	0-9
10742108-5	2000	Crh has a higher affinity for Crhr1 than for Crhr2, and urocortin (Ucn), a Crh-related peptide, is thought to be the endogenous ligand for Crhr2 because it binds with almost 40-fold higher affinity than does Crh.	Urocortins	56-65	urocortin	Mus musculus	67-70
10742108-5	2000	Crh has a higher affinity for Crhr1 than for Crhr2, and urocortin (Ucn), a Crh-related peptide, is thought to be the endogenous ligand for Crhr2 because it binds with almost 40-fold higher affinity than does Crh.	Urocortins	56-65	corticotropin releasing hormone receptor 2	Mus musculus	139-144
10777063-4	2000	Binding of iodine 125 CRH to intact keratinocytes was inhibited by increasing doses of CRH, sauvagine, or urocortin, all showing equal inhibitory potency.	Urocortins	106-115	corticotropin releasing hormone	Homo sapiens	22-25
10650129-3	2000	injection of CRF and urocortin in conscious rats by monitoring Fos expression 60 min later.	Urocortins	21-30	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	63-66
10650150-6	2000	Icv injection of CRH and urocortin also suppressed the ConA response of splenic lymphocytes, and the effect of urocortin was prevented by the anti-CRH antibody, while that of CRH was not prevented by the anti-urocortin antibody.	Urocortins	111-120	corticotropin releasing hormone	Rattus norvegicus	17-20
10650150-6	2000	Icv injection of CRH and urocortin also suppressed the ConA response of splenic lymphocytes, and the effect of urocortin was prevented by the anti-CRH antibody, while that of CRH was not prevented by the anti-urocortin antibody.	Urocortins	111-120	corticotropin releasing hormone	Rattus norvegicus	147-150
10650150-6	2000	Icv injection of CRH and urocortin also suppressed the ConA response of splenic lymphocytes, and the effect of urocortin was prevented by the anti-CRH antibody, while that of CRH was not prevented by the anti-urocortin antibody.	Urocortins	111-120	corticotropin releasing hormone	Rattus norvegicus	147-150
10650150-7	2000	These results suggest that leptin suppresses peripheral lymphocyte functions, in contrast to the direct activating effects, indirectly through the activation of the CRH (urocortin)-sympathetic nervous system.	Urocortins	170-179	corticotropin releasing hormone	Rattus norvegicus	165-168
10875227-9	2000	The multifactorial regulation of CRF R2beta mRNA expression in the cardiovascular system may serve to limit the inotropic and chronotropic effects of CRF R2 agonists such as urocortin during prolonged physical or immune challenge.	Urocortins	174-183	corticotropin releasing hormone receptor 2	Rattus norvegicus	33-39
10837794-0	2000	Long-term effects on feeding and body weight after stimulation of forebrain or hindbrain CRH receptors with urocortin.	Urocortins	108-117	corticotropin releasing hormone	Rattus norvegicus	89-92
10690896-1	2000	Since the skin produces POMC peptides, in the present work we investigated local production of urocortin, a peptide related to CRH, the normal endogenous stimulant for POMC.	Urocortins	95-104	proopiomelanocortin	Homo sapiens	168-172
10656997-4	2000	The human CRF-BP ligand was found to: (a) possess a molecular mass of 4707 Daltons, (b) have an N-terminal amino acid sequence (5 residues) identical to rat urocortin, (c) be detected by a specific urocortin radioimmunoassay, (d) have high affinity for both the human and ovine CRF-BPs and (e) be present in many regions of the ovine brain.	Urocortins	157-166	corticotropin releasing hormone binding protein	Homo sapiens	10-16
10656997-4	2000	The human CRF-BP ligand was found to: (a) possess a molecular mass of 4707 Daltons, (b) have an N-terminal amino acid sequence (5 residues) identical to rat urocortin, (c) be detected by a specific urocortin radioimmunoassay, (d) have high affinity for both the human and ovine CRF-BPs and (e) be present in many regions of the ovine brain.	Urocortins	198-207	corticotropin releasing hormone binding protein	Homo sapiens	10-16
10656997-9	2000	We conclude that urocortin is the principal ligand for the CRF-BP in ovine brain and we could find no evidence for a centrally located mammalian sauvagine-like peptide.	Urocortins	17-26	corticotropin releasing hormone binding protein	Homo sapiens	59-65
10648719-6	2000	Unique sites of CRF-R2 expression were relatively unresponsive to CRF but were more so after icv administration of urocortin (UCN), a new mammalian CRF-related peptide.	Urocortins	115-124	corticotropin releasing hormone receptor 2	Homo sapiens	16-22
10648719-6	2000	Unique sites of CRF-R2 expression were relatively unresponsive to CRF but were more so after icv administration of urocortin (UCN), a new mammalian CRF-related peptide.	Urocortins	115-124	urocortin	Homo sapiens	126-129
10818395-5	2000	A local CRF-BP modulates the paracrine effects of CRF and urocortin.	Urocortins	58-67	corticotropin releasing hormone binding protein	Homo sapiens	8-14
11268356-7	2000	We and others could show that lymphocytes are one source of immunoreactive CRH; however, the antiserum used in our study as well as in previous reports crossreacted with urocortin, a newly discovered member of the CRH family.	Urocortins	170-179	corticotropin releasing hormone	Homo sapiens	75-78
11268356-7	2000	We and others could show that lymphocytes are one source of immunoreactive CRH; however, the antiserum used in our study as well as in previous reports crossreacted with urocortin, a newly discovered member of the CRH family.	Urocortins	170-179	corticotropin releasing hormone	Homo sapiens	214-217
10614646-2	2000	The physiological role of urocortin is unknown, but it has been postulated to serve some of the functions previously attributed to CRH.	Urocortins	26-35	corticotropin releasing hormone	Mus musculus	131-134
10630405-3	1999	Exogenous urocortin is more potent than corticotropin releasing hormone (CRH) in protecting cardiac myocytes from necrotic and apoptotic death induced by ischaemia, and the cardioprotective effects of ischaemia-preconditioned media are abrogated by antagonists to the CRH family of peptides.	Urocortins	10-19	corticotropin releasing hormone	Rattus norvegicus	268-271
10612445-0	1999	High-affinity binding of urocortin and astressin but not CRF to G protein-uncoupled CRFR1.	Urocortins	25-34	corticotropin releasing hormone receptor 1	Rattus norvegicus	84-89
10393986-4	1999	The other known mammalian ligand for CRH receptors is urocortin.	Urocortins	54-63	corticotropin releasing hormone	Homo sapiens	37-40
10535410-2	1999	However, urocortin, sauvagine, and urotensin, other members of the family of CRH-like molecules, have also been shown to be potent inhibitors of food intake.	Urocortins	9-18	corticotropin releasing hormone	Mus musculus	77-80
10417230-11	1999	Both fish neuropeptides possessed an order of magnitude less potency than human urocortin in CRF-R2 transfected cells.	Urocortins	80-89	corticotropin releasing hormone receptor 2	Homo sapiens	93-99
10500222-7	1999	The increased anorectic and anxiogenic-like behavior most likely is caused by increased "free" CRH and/or urocortin levels in the brain of CRH-BP-deficient animals, suggesting an important role for CRH-BP in maintaining appropriate levels of these peptides in the central nervous system.	Urocortins	106-115	corticotropin releasing hormone binding protein	Mus musculus	139-145
10027877-0	1999	Potent mast cell degranulation and vascular permeability triggered by urocortin through activation of corticotropin-releasing hormone receptors.	Urocortins	70-79	corticotropin releasing hormone	Rattus norvegicus	102-133
10198329-1	1999	Urocortin, a new mammalian member of the corticotropin-releasing factor (CRF) family has been proposed to be the endogenous ligand for CRF receptor 2 (CRF-R2).	Urocortins	0-9	corticotropin releasing hormone	Homo sapiens	41-71
10198329-1	1999	Urocortin, a new mammalian member of the corticotropin-releasing factor (CRF) family has been proposed to be the endogenous ligand for CRF receptor 2 (CRF-R2).	Urocortins	0-9	corticotropin releasing hormone receptor 2	Homo sapiens	135-149
10198329-1	1999	Urocortin, a new mammalian member of the corticotropin-releasing factor (CRF) family has been proposed to be the endogenous ligand for CRF receptor 2 (CRF-R2).	Urocortins	0-9	corticotropin releasing hormone receptor 2	Homo sapiens	151-157
10198329-4	1999	At these intravenous doses, CRF and urocortin have their actions fully reversed by the CRF-R1/CRF-R2 antagonist astressin at antagonist/agonist ratios of 5:1 and 67:1, respectively.	Urocortins	36-45	corticotropin releasing hormone receptor 1	Rattus norvegicus	87-93
10198329-4	1999	At these intravenous doses, CRF and urocortin have their actions fully reversed by the CRF-R1/CRF-R2 antagonist astressin at antagonist/agonist ratios of 5:1 and 67:1, respectively.	Urocortins	36-45	corticotropin releasing hormone receptor 2	Rattus norvegicus	94-100
10198329-7	1999	These results as well as earlier ones showing that alpha-helical CRF9-41 (a CRF-R2 more selective antagonist) partly prevented postoperative ileus indicate that peripheral CRF-R2 may be primarily involved in intravenous urocortin-, CRF-, and abdominal surgery-induced gastric stasis.	Urocortins	220-229	corticotropin releasing hormone receptor 2	Rattus norvegicus	172-178
10199789-11	1999	A dose-related increase of trophoblast ACTH or PGE2 was induced by urocortin, whereas astressin inhibited urocortin-stimulated ACTH or PGE2 release.	Urocortins	106-115	proopiomelanocortin	Homo sapiens	127-131
10199789-14	1999	The present study showed that human urocortin stimulates placental secretion of ACTH and PGE2, and modulates myometrial contractility, suggesting a role for this peptide in placental and intrauterine CRF pathways.	Urocortins	36-45	proopiomelanocortin	Homo sapiens	80-84
10448894-6	1999	This slower dissociation indicates that the CRF-BP may be more effective in clearing urocortin than CRF.	Urocortins	85-94	corticotropin releasing hormone binding protein	Homo sapiens	44-50
10199789-4	1999	The aim of the present study was to evaluate the effect of urocortin on placental ACTH and prostaglandin (PG) secretion, as well as on myometrial contractility.	Urocortins	59-68	proopiomelanocortin	Homo sapiens	82-86
10199789-6	1999	For investigating the effect of urocortin on ACTH release, primary cultures of human trophoblast cells were used.	Urocortins	32-41	proopiomelanocortin	Homo sapiens	45-49
10199789-11	1999	A dose-related increase of trophoblast ACTH or PGE2 was induced by urocortin, whereas astressin inhibited urocortin-stimulated ACTH or PGE2 release.	Urocortins	67-76	proopiomelanocortin	Homo sapiens	39-43
10392850-1	1999	Urocortin, a novel 40 amino acid neuropeptide, is a member of the corticotropin-releasing factor family.	Urocortins	0-9	corticotropin releasing hormone	Rattus norvegicus	66-96
9886092-6	1999	Mutation of Arg76 or Asn81 but not Gly83 of hCRF-R1 to the corresponding amino acids of xCRF-R1 or hVIP-R2 resulted in 100-1,000-fold lower affinities for human/rat CRF, rat urocortin, and astressin.	Urocortins	174-183	vasoactive intestinal peptide receptor 2	Homo sapiens	99-106
10392850-2	1999	With 45% homology to corticotropin-releasing factor, urocortin binds with similar affinity to the corticotropin-releasing factor- and corticotropin-releasing factor-2 receptors and may play a role in modulating many of the same systems as corticotropin-releasing factor.	Urocortins	53-62	corticotropin releasing hormone	Rattus norvegicus	21-51
10392850-2	1999	With 45% homology to corticotropin-releasing factor, urocortin binds with similar affinity to the corticotropin-releasing factor- and corticotropin-releasing factor-2 receptors and may play a role in modulating many of the same systems as corticotropin-releasing factor.	Urocortins	53-62	corticotropin releasing hormone	Rattus norvegicus	98-128
10392850-2	1999	With 45% homology to corticotropin-releasing factor, urocortin binds with similar affinity to the corticotropin-releasing factor- and corticotropin-releasing factor-2 receptors and may play a role in modulating many of the same systems as corticotropin-releasing factor.	Urocortins	53-62	corticotropin releasing hormone	Rattus norvegicus	98-128
10392850-2	1999	With 45% homology to corticotropin-releasing factor, urocortin binds with similar affinity to the corticotropin-releasing factor- and corticotropin-releasing factor-2 receptors and may play a role in modulating many of the same systems as corticotropin-releasing factor.	Urocortins	53-62	corticotropin releasing hormone	Rattus norvegicus	98-128
9926843-1	1998	To assess the possible role of urocortin, a recently identified neuropeptide related to corticotropin-releasing factor (CRF), in modulation of peripheral immune functions, the effects of intracranially administrated urocortin on the proliferative activity of splenic lymphocytes were examined in rats.	Urocortins	31-40	corticotropin releasing hormone	Rattus norvegicus	88-118
9449626-6	1998	The complementary chimera in which E1 domain of the GRF-R was replaced by that of the CRF-R1 bound astressin and urocortin with Ki values approximately 10 nM, compared with inhibitory binding dissociation constant (Ki) values of approximately 2-4 nM for the wild-type CRF-R1.	Urocortins	113-122	corticotropin releasing hormone receptor 1	Rattus norvegicus	86-92
9851801-9	1998	The CRH receptor antagonist, alpha-helical CRH-(9-41) (0.2 nmol/L) significantly attenuated the vasodilatation produced by urocortin, urotensin-1, and CRH (P < 0.05).	Urocortins	123-132	corticotropin releasing hormone	Homo sapiens	4-7
9851801-9	1998	The CRH receptor antagonist, alpha-helical CRH-(9-41) (0.2 nmol/L) significantly attenuated the vasodilatation produced by urocortin, urotensin-1, and CRH (P < 0.05).	Urocortins	123-132	corticotropin releasing hormone	Homo sapiens	43-46
9851801-9	1998	The CRH receptor antagonist, alpha-helical CRH-(9-41) (0.2 nmol/L) significantly attenuated the vasodilatation produced by urocortin, urotensin-1, and CRH (P < 0.05).	Urocortins	123-132	corticotropin releasing hormone	Homo sapiens	43-46
9791062-4	1998	In addition, an intraperitoneal injection of h/rCRF (100 micrograms/kg) or rat urocortin (10 and 100 micrograms/kg) increased the plasma IL-6 activity, mimicking the response to immobilization.	Urocortins	79-88	interleukin 6	Rattus norvegicus	137-141
9863643-0	1998	Characterization of the relaxant action of urocortin, a new peptide related to corticotropin-releasing factor in the rat isolated basilar artery.	Urocortins	43-52	corticotropin releasing hormone	Rattus norvegicus	79-109
9863643-15	1998	The results suggest that urocortin induces relaxation of cerebral arteries by activating CRF-R2 receptors present in the vascular wall.	Urocortins	25-34	corticotropin releasing hormone receptor 2	Rattus norvegicus	89-95
9655891-5	1998	The rank order potency of peptide analogs of CRH to inhibit [125I]tyr(o)sauvagine binding to CRH2 alpha receptors was: urotensin > sauvagine = urocortin > alpha-helical CRH9-41 > rh-CRH >> o-CRH.	Urocortins	146-155	corticotropin releasing hormone	Homo sapiens	45-48
9731865-1	1998	OBJECTIVES: The aim of this study was to investigate the possibility that urocortin is the ligand that displaces corticotropin-releasing hormone from its binding protein in the maternal circulation during pregnancy and, if so, to determine whether urocortin, like corticotropin-releasing hormone, is synthesized in substantial quantities in the placenta.	Urocortins	74-83	corticotropin releasing hormone	Homo sapiens	113-144
9731865-1	1998	OBJECTIVES: The aim of this study was to investigate the possibility that urocortin is the ligand that displaces corticotropin-releasing hormone from its binding protein in the maternal circulation during pregnancy and, if so, to determine whether urocortin, like corticotropin-releasing hormone, is synthesized in substantial quantities in the placenta.	Urocortins	74-83	corticotropin releasing hormone	Homo sapiens	264-295
9654364-0	1998	Central administration of urocortin inhibits vasopressin release in conscious rats.	Urocortins	26-35	arginine vasopressin	Rattus norvegicus	45-56
9631473-0	1998	The role of CRF2 receptors in corticotropin-releasing factor- and urocortin-induced anorexia.	Urocortins	66-75	corticotropin releasing hormone receptor 2	Rattus norvegicus	12-16
9631473-1	1998	The experiments presented in this study were designed to assess corticotropin-releasing factor (CRF) receptor subtype mediation of CRF- and urocortin (UCN)-induced decrease in food intake.	Urocortins	140-149	corticotropin releasing hormone	Rattus norvegicus	64-94
9631473-1	1998	The experiments presented in this study were designed to assess corticotropin-releasing factor (CRF) receptor subtype mediation of CRF- and urocortin (UCN)-induced decrease in food intake.	Urocortins	151-154	corticotropin releasing hormone	Rattus norvegicus	64-94
9786168-10	1998	On the other hand substitutions at residues 4 or 5 in r-urocortin or h/r-CRH respectively appear to decrease activity at CRH1 but not CRH2beta receptors The modified CRH and urocortin analogs described here may provide clues for the further design of receptor selective ligands.	Urocortins	56-65	corticotropin releasing hormone	Rattus norvegicus	121-124
9180220-1	1997	The effect of chronic salt loading on urocortin-like immunoreactivity (Ucn-IR) was investigated in the rat hypothalamo-neurohypophysial system.	Urocortins	38-47	urocortin	Rattus norvegicus	71-74
9415408-7	1997	These data could, at least in part, account for the much higher affinity of CRFR2 for urocortin and sauvagine compared with rat/human CRF.	Urocortins	86-95	corticotropin releasing hormone receptor 2	Rattus norvegicus	76-81
9348237-9	1997	These results are consistent with a role for CRF2 activation in mediating some of the complex interactions of CRF (or urocortin) with regulation of food intake in the developing rat.	Urocortins	118-127	corticotropin releasing hormone receptor 2	Rattus norvegicus	45-49
9423932-6	1997	Thus, for the recombinant CRF1 receptor, binding was inhibited with similar affinity by Urocortin, sauvagine, Urotensin 1 and CRF.	Urocortins	88-97	corticotropin releasing hormone receptor 1	Homo sapiens	26-30
9423932-9	1997	The pharmacological profile of specific [3H]-urocortin binding to homogentates of rat cerebellum was consistent with specific labelling of a CRF1 receptor.	Urocortins	45-54	corticotropin releasing hormone receptor 1	Homo sapiens	141-145
7477349-5	1995	Synthetic urocortin evokes secretion of adrenocorticotropic hormone (ACTH) both in vitro and in vivo and binds and activates transfected type-1 CRF receptors, the subtype expressed by pituitary corticotropes.	Urocortins	10-19	proopiomelanocortin	Homo sapiens	40-67
9189917-1	1997	Potential anxiogenic-like properties of urocortin, a corticotropin-releasing factor (CRF)-related neuropeptide, were investigated in models of anxiety in rodents.	Urocortins	40-49	corticotropin releasing hormone	Mus musculus	53-83
8986836-2	1996	A protein that binds CRF and the related peptide, urocortin, with high affinity, CRF-binding protein (CRF-BP), may play a role in energy homeostasis by inactivating members of this peptide family in ingestive and metabolic regulatory brain regions.	Urocortins	50-59	corticotropin releasing hormone binding protein	Rattus norvegicus	81-100
8986836-2	1996	A protein that binds CRF and the related peptide, urocortin, with high affinity, CRF-binding protein (CRF-BP), may play a role in energy homeostasis by inactivating members of this peptide family in ingestive and metabolic regulatory brain regions.	Urocortins	50-59	corticotropin releasing hormone binding protein	Rattus norvegicus	102-108
8986836-3	1996	Intracerebroventricular administration in rats of the high-affinity CRF-BP ligand inhibitor, rat/human CRF (6-33), which dissociates CRF or urocortin from CRF-BP and increases endogenous brain levels of "free" CRF or urocortin significantly blunted exaggerated weight gain in Zucker obese subjects and in animals withdrawn from chronic nicotine.	Urocortins	140-149	corticotropin releasing hormone binding protein	Rattus norvegicus	68-74
8986836-3	1996	Intracerebroventricular administration in rats of the high-affinity CRF-BP ligand inhibitor, rat/human CRF (6-33), which dissociates CRF or urocortin from CRF-BP and increases endogenous brain levels of "free" CRF or urocortin significantly blunted exaggerated weight gain in Zucker obese subjects and in animals withdrawn from chronic nicotine.	Urocortins	217-226	corticotropin releasing hormone binding protein	Rattus norvegicus	68-74
8836534-0	1996	Urocortin interaction with corticotropin-releasing factor (CRF) binding protein (CRF-BP): a novel mechanism for elevating "free" CRF levels in human brain.	Urocortins	0-9	corticotropin releasing hormone binding protein	Homo sapiens	27-79
8836534-0	1996	Urocortin interaction with corticotropin-releasing factor (CRF) binding protein (CRF-BP): a novel mechanism for elevating "free" CRF levels in human brain.	Urocortins	0-9	corticotropin releasing hormone binding protein	Homo sapiens	81-87
8836534-1	1996	Here we demonstrate that urocortin, a new mammalian member of the corticotropin-releasing factor (CRF) neuropeptide family has high affinity for both the recombinant human CRF binding protein (CRF-BP) and for a membrane-associated form of the protein solubilized from postmortem human cerebrocortical brain tissue.	Urocortins	25-34	corticotropin releasing hormone	Homo sapiens	66-96
8836534-1	1996	Here we demonstrate that urocortin, a new mammalian member of the corticotropin-releasing factor (CRF) neuropeptide family has high affinity for both the recombinant human CRF binding protein (CRF-BP) and for a membrane-associated form of the protein solubilized from postmortem human cerebrocortical brain tissue.	Urocortins	25-34	corticotropin releasing hormone binding protein	Homo sapiens	172-191
8836534-1	1996	Here we demonstrate that urocortin, a new mammalian member of the corticotropin-releasing factor (CRF) neuropeptide family has high affinity for both the recombinant human CRF binding protein (CRF-BP) and for a membrane-associated form of the protein solubilized from postmortem human cerebrocortical brain tissue.	Urocortins	25-34	corticotropin releasing hormone binding protein	Homo sapiens	193-199
8836534-2	1996	The rank order of binding potency for both the human recombinant CRF-BP and for the solubilized human brain CRF-BP is: urotensin > hCRF > urocortin > sauvagine.	Urocortins	144-153	corticotropin releasing hormone binding protein	Homo sapiens	65-71
8836534-2	1996	The rank order of binding potency for both the human recombinant CRF-BP and for the solubilized human brain CRF-BP is: urotensin > hCRF > urocortin > sauvagine.	Urocortins	144-153	corticotropin releasing hormone binding protein	Homo sapiens	108-114
8836534-5	1996	Incubation of human brain postmortem tissue extracts with urocortin and urotensin resulted in a dramatic decrease in hCRF/hCRF-BP levels and a concomitant increase in "free" hCRF levels.	Urocortins	58-67	corticotropin releasing hormone	Homo sapiens	117-121
8836534-5	1996	Incubation of human brain postmortem tissue extracts with urocortin and urotensin resulted in a dramatic decrease in hCRF/hCRF-BP levels and a concomitant increase in "free" hCRF levels.	Urocortins	58-67	corticotropin releasing hormone binding protein	Homo sapiens	122-129
8836534-5	1996	Incubation of human brain postmortem tissue extracts with urocortin and urotensin resulted in a dramatic decrease in hCRF/hCRF-BP levels and a concomitant increase in "free" hCRF levels.	Urocortins	58-67	corticotropin releasing hormone	Homo sapiens	122-126
9118350-7	1996	These data indicate that CRF receptor antagonists may be useful for the treatment of the disease states where CRF is elevated such as anxiety and depression, anorexia nervosa and stroke and that ligand inhibitors of CRF-BP may be used to elevate brain levels of "free" urocortin and other CRF-related peptides.	Urocortins	269-278	corticotropin releasing hormone binding protein	Homo sapiens	216-222
7477349-5	1995	Synthetic urocortin evokes secretion of adrenocorticotropic hormone (ACTH) both in vitro and in vivo and binds and activates transfected type-1 CRF receptors, the subtype expressed by pituitary corticotropes.	Urocortins	10-19	corticotropin releasing hormone receptor 1	Homo sapiens	137-157
7477349-6	1995	The coincidence of urotensin-like immunoreactivity with type-2 CRF receptors in brain, and our observation that urocortin is more potent than CRF at binding and activating type-2 CRF receptors, as well as at inducing c-Fos (an index of cellular activation) in regions enriched in type-2 CRF receptors, indicate that this new peptide could be an endogenous ligand for type-2 CRF receptors.	Urocortins	112-121	corticotropin releasing hormone receptor 2	Homo sapiens	172-192
7477349-6	1995	The coincidence of urotensin-like immunoreactivity with type-2 CRF receptors in brain, and our observation that urocortin is more potent than CRF at binding and activating type-2 CRF receptors, as well as at inducing c-Fos (an index of cellular activation) in regions enriched in type-2 CRF receptors, indicate that this new peptide could be an endogenous ligand for type-2 CRF receptors.	Urocortins	112-121	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	217-222
7477349-6	1995	The coincidence of urotensin-like immunoreactivity with type-2 CRF receptors in brain, and our observation that urocortin is more potent than CRF at binding and activating type-2 CRF receptors, as well as at inducing c-Fos (an index of cellular activation) in regions enriched in type-2 CRF receptors, indicate that this new peptide could be an endogenous ligand for type-2 CRF receptors.	Urocortins	112-121	corticotropin releasing hormone receptor 2	Homo sapiens	172-192
7477349-6	1995	The coincidence of urotensin-like immunoreactivity with type-2 CRF receptors in brain, and our observation that urocortin is more potent than CRF at binding and activating type-2 CRF receptors, as well as at inducing c-Fos (an index of cellular activation) in regions enriched in type-2 CRF receptors, indicate that this new peptide could be an endogenous ligand for type-2 CRF receptors.	Urocortins	112-121	corticotropin releasing hormone receptor 2	Homo sapiens	172-192